Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Gm Wb, your ABK is still climbing slowly. Had to give you a big membermark for all your great calls
.<font color=green> Todays Green List : FSLR ABPI ___ ____ ___
add to the list please.
(nasd) ***VRSO*Verso Tech-VRSO trading halted, pending news
Wednesday, April 30 2008 - 8:20
$0.0181 $-0.0119 (%-39.67)
(nasd) ****ECTX $2.19ECtel Expected to Strengthen IRM(TM) Market Position with Acquisition of Compwise''s Assets
Wednesday, April 30 2008 - 8:02
$0.01 (%0.46)
ROSH HA'AYIN, Israel, April 30 /PRNewswire-FirstCall/ -- ECtel Ltd. (NASDAQ: ECTX), a leading provider of Integrated Revenue Management(TM) (IRM(TM)) solutions, announced today that it acquired substantially all assets of Israel-based Compwise, a provider of business analytic solutions for telecommunication operators, for approximately $1.3 million.
(Logo: http://www.newscom.com/cgi-bin/prnh/20010807/FLTU015LOGO )
The acquisition is expected to expand and strengthen ECtel's market leading Integrated Revenue Management(TM) product suite, as well as expand its customer base. The acquisition is expected to be accretive to earnings.
Compwise's products provide innovative business intelligence solutions for telecommunications service providers. Their unique analytical approach enables operators to maximize tariff profitability, improve retention of profitable customers and detect revenue leakage.
ECtel will merge Compwise's products into ECtel's leading IRM(TM) platform, further enhancing the Company's offering as a one-stop revenue management solution. Under terms of the acquisition, ECtel will continue to provide revenue management services and support to Compwise's current clients, which include some of the leading and most well-known telecom service providers around the world.
"By incorporating Compwise's product offering, ECtel will further improve its ability to assist telcos with their revenue management efforts," said Itzik Weinstein, CEO of ECtel. "This transaction showcases our long-term commitment to provide our customers with the most innovative and complete revenue management solution available in the market today."
"The acquisition is well aligned with our long-term growth strategy, which focuses on solid execution, innovation and M&A activity," Weinstein added. "Compwise's products add a set of business intelligence capabilities that will enable the operator to address pricing and profitability, customer retention, marketing campaigns and rating & billing assurance."
About ECtel
ECtel (NASDAQ:ECTX) is a leading global provider of Integrated Revenue Management(TM) (IRM(TM)) solutions for communications service providers. A pioneering market leader for nearly 20 years, ECtel offers carrier-grade solutions that enable wireline, wireless, converged and next generation operators to fully manage their revenue and cost processes. ECtel serves prominent Tier One operators, and has more than 100 implementations in over 50 countries worldwide. Established in 1990, ECtel maintains offices in the Americas and Europe. For more information, visit http://www.ectel.com
Certain statements contained in this release contain forward-looking information with respect to benefits of the proposed acquisition, expectations that the acquisition will be accretive to ECtel's results and plans, projections or future performance and products of the Company, the occurrence of which involves certain risks and uncertainties, including, but not limited to, difficulties encountered in integrating the acquired business, approval of the transaction by the stockholders of Compwise, the satisfaction of closing conditions to the transaction, the risk that liabilities assumed in this acquisition will be greater than anticipated, the reoccurrence of sales to existing customers, the ability to recognize revenue in future periods as anticipated, the possible slow-down in expenditures by telecom operators, the unpredictability of the telecom market, product and market acceptance risks, ability to complete development and market introduction of new products, the impact of competitive pricing and offerings, fluctuations in quarterly and annual results of operations, dependence on several large customers, commercialization and technological difficulties, risks related to our operations in Israel and other risks detailed in the Company's annual report on Form 20-F and other filings with the Securities and Exchange Commission. ECtel undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
SOURCE ECtel Ltd
(nasd) ZICA $0.52T-Mobile Extends Rollout of Zi Corporation''s Qix
Wednesday, April 30 2008 - 8:01
$0.01 (%1.96)
CALGARY, ALBERTA -- (MARKET WIRE) -- 04/30/08 -- Zi Corporation (TSX: ZIC)(NASDAQ: ZICA) (the "Company" or "Zi"), the leading innovator of mobile discovery & advertising solutions, today announced that Qix(TM), will be offered as a download version to T-Mobile customers in the UK. Qix will be available on select device models on the T-Mobile network effective immediately.
Qix is a mobile discovery solution that allows users to access the mobile handset's full range of features, both on and off device, simply and intuitively. Qix was initially integrated onto the N70 handset on the T-Mobile network in the UK last year and this new expansion phase will see this product made available to more T-Mobile users.
Steve Buck, Head of Products for T-Mobile UK said "By providing a download capability Zi has enabled T-Mobile to provide the latest version of Qix software both to new handsets and to a larger volume of existing handsets already in use."
Milos Djokovic, President and CEO of Zi Corporation said, "T-Mobile is one of the UK's leading operators and this extended rollout will introduce more T-Mobile users to Qix. We are delighted to be extending our relationship with T-Mobile and look forward to showing how Qix can deliver the latest services and relevant content suggestions to their subscribers."
The downloadable version is available to a selected number of T-Mobile UK subscribers with Nokia models N95, N73, 6120c and E51. Subscribers can download the software directly from T-Mobile's Web'n'Walk HomePage or from qix.zicorp.com/tmobile.
About Zi Corporation
Zi Corporation is a leading provider of discovery and usability solutions for Mobile Search, Input and Advertising. Zi Corporation's suite of award-winning products offers innovative ways for mobile operators to showcase new services and content to their subscribers, while encouraging users to get the most out of their communication devices. Increased device usage can help mobile operators drive additional revenues and lead to improved customer retention.
Zi products are featured on more than 1000 handset models and implemented across most technology platforms in the market today.
Zi is a software company committed exclusively to evolving its innovative product family in support of its licensees worldwide. A publicly traded company, Zi Corporation is listed on NASDAQ (ZICA) and the Toronto Stock Exchange (ZIC). For more information, please visit zicorp.com.
This release may be deemed to contain forward-looking statements, which are subject to the safe harbour provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among other things, statements regarding future events and the future financial performance of Zi Corporation that involve risks and uncertainties. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results due to a variety of factors, including: the growth trends in the input technology industry; new product development; global economic conditions and uncertainties in the geopolitical environment; financial and operating performance of Zi OEM customers and variations in their customer demand for products and services; the ability to successfully acquire businesses and technologies and to successfully integrate and operate these acquired businesses and technologies; dependence on the introduction and market acceptance of new product offerings and standards; rapid technological and market change; matters affecting Zi Corporation's significant shareholder; litigation involving patents, intellectual property, and other matters; the ability to recruit and retain key personnel; Zi Corporation's ability to manage financial risk; currency fluctuations and other international factors; potential volatility in operating results and other factors listed in Zi Corporation's filings with the Securities and Exchange Commission. Any projections in this release are based on limited information currently available to Zi Corporation, which is subject to change. Although any such projections and the factors influencing them will likely change, except to the extent required by law, Zi Corporation will not necessarily update the information. Such information speaks only as of the date of this release.
Zi, eZiType, eZiText, Decuma and Qix are registered trademarks of Zi and/or its subsidiaries. All other trademarks are the property of their respective owners.
To view the accompanying image of Qix for T-Mobile please visit the following link:
http://media3.marketwire.com/docs/qix.jpg
Contacts:
For Zi Corporation:
BCS PR
Emma Tagg
+44 (0) 115 948 6901
Email: emma@bcspr.co.uk
BCS PR
Jessica Culshaw
+44 (0) 115 948 6901
Email: jessica@bcspr.co.uk
CAMERON Associates
Ray Catroppa
(212) 245-8800
Email: ray@cameronassoc.com
CAMERON Associates
Al Palombo
(212) 245-8800
Email: al@cameronassoc.com
CAMERON Associates
Devin Rhoades
(212) 245-8800
Email: devin@cameronassoc.com
(nasd) ****TSYS $3.536TCS Awarded $15.8 Million in Government Contracts
Wednesday, April 30 2008 - 8:01
$-0.134 (%-3.65)
ANNAPOLIS, MD -- (MARKET WIRE) -- 04/30/08 -- TeleCommunication Systems, Inc. (TCS) (NASDAQ: TSYS), a leading provider of mission-critical wireless communications, today announced that it has recently secured approximately $15.8 million in contracts to provide a broad range of communication solutions and services primarily to Federal Government customers across Civilian Agencies, the Department of Homeland Security, and the Department of Defense (DoD). TCS was contracted to provide solutions to include SwiftLink products, satellite communications services, Continuity of Operations (COOP), and Telecom Expense Management (TEM).
The contracts awarded to TCS in the past four months derive from multiple sales vehicles, including the company's GSA Schedule, the World-Wide Satellite Systems (WWSS) Indefinite Delivery Indefinite Quantity (IDIQ) contract, Washington Interagency Telecommunications System (WITS) and the GSA SATCOM-II Contract. A full list of contract vehicles can be found at: http://www1.telecomsys.com/government/nsg_contract_vehicles/ContractVehicles.cfm.
"These contract wins demonstrate our continued ability to meet the government's stringent requirements for providing best-in-class communications services and solutions," said Michael Bristol, Senior Vice President of the Government Services Group at TCS. "TCS strives to understand each organization's needs and timeframes to deliver the tools and resources necessary to get the job done, efficiently and effectively. Our solid reputation and proven performance are generating an increase in government contracts."
The consistent contract deal flow that TCS maintains is attributed to a strong 20-year track record of delivering premium quality professional services that include:
-- The SwiftLink® deployable communication suite provides government
organizations with battle tested, reliable connectivity and empowers
warfighters with seamless, secure interoperable communications.
http://www.telecomsys.com/government/swiftlink/index.cfm
-- TCS Satellite Services provide technically advanced international
satellite communications. With experience in design, installation,
operation, service, and maintenance, TCS offers flexible and easy-to-use
communications capabilities. TCS manages the entire network integration
effort -- from international licensing and project management to network
design, site surveys, antenna installation, satellite commissioning, and
network maintenance.
http://www.telecomsys.com/government/satelliteservices.cfm
-- TCS COOP solutions are customizable, employing proven continuity of
operations methodologies and cutting-edge technologies for any government
sector or industry to ensure continuity of mission-essential functions
during an emergency. http://www.telecomsys.com/government/Coop_overview.cfm
-- The TCS TEM solution equips managers with tools to organize and reduce
telecom expenditures. TCS TEM increases visibility and cost efficiency,
empowering managers to introduce newer telecom technologies and redirect
resources to other pressing needs.
http://www.telecomsys.com/government/TelecomExpMgmt.cfm
About TeleCommunication Systems, Inc.
TeleCommunication Systems, Inc. (TCS) (NASDAQ: TSYS) produces wireless data communications technology solutions that require proven high levels of reliability. TCS provides wireless and VoIP E9-1-1 network-based services, secure deployable communication systems, engineered satellite-based services, and commercial location applications, like traffic and navigation, using the precise location of a wireless device. Customers include leading wireless, cable MSOs, and VoIP carriers around the world, and agencies of the U.S. Departments of Defense, State, and Homeland Security. For more information, visit www.telecomsys.com.
Except for the historical information contained herein, this news release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. These statements are subject to risks and uncertainties and are based upon TCS' current expectations and assumptions that if incorrect would cause actual results to differ materially from those anticipated. Risks include the possibility that not that all of the potential revenue under the contracts will be realized, given federal contract provisions allowing for termination for convenience, and those detailed from time to time in the Company's SEC reports, including the report on Form 10-K for the year ended December 31, 2007.
Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to update or revise the information in this press release, whether as a result of new information, future events or circumstances, or otherwise.
(nasd) ELTK $2.20STABLCOR Launches Price Competitive ST10-LC909 Product for CTE Control in Polyimide Applications
Wednesday, April 30 2008 - 8:00
$-0.0199 (%-0.90)
COSTA MESA, CA -- (MARKET WIRE) -- 04/30/08 -- STABLCOR Incorporated, a provider of laminate-based thermal management technology for printed circuit boards and substrates, announced the launch of their ST10 Polyimide product family.
According to STABLCOR Chief Technology Officer Kris Vasoya, the new ST10-LC909 (Polyimide) is a more reliable, price competitive replacement product for use in controlling the thermal expansion of printed circuit boards and matches closer with the Ceramic and flip-chip type low CTE components. ST10-LC909 is the industry alternative product for Thermount® and Copper Invar Copper.
"The ability to control CTE, until now, was limited to Epoxy-based applications only," said Vasoya. "With our competitive pricing, ST10-LC909 can cost effectively be used in polyimide-based, low CTE applications and presents a significant advantage to Thermount® users. We worked closely in the development of this product with two of our major fabricators, Eltek Ltd. (NASDAQ: ELTK) and CIREP, a subsidiary of France-based CIRE Group. ST10-LC909 has been extensively tested by an independent laboratory," added Vasoya.
A multi-layer board manufactured with polyimide and Copper Invar Copper, or Thermount materials can be duplicated using multiple layers of standard polyimide and two to three layers of ST10-LC909 embedded into the PCB to achieve the Coefficient of Thermal Expansion (CTE) replicating an existing design. An additional benefit of using STABLCOR is the ability to tailor the CTE in a range from 9ppm/°C to 12ppm/°C. Achieving this significant advantage is dependent on the placement and amount of material used in the PCB stack-up. To view CTE comparison test results with boards using Thermount and those manufactured with STABLCOR, visit the company's website at www.stablcor.com.
"The launch of our ST10-LC909 family will provide a product that fills a significant unmet need within the PCB industry," commented Stablcor President Douglas J. Tullio. "While we currently have an extensive intellectual portfolio of five issued and 20 domestic and international patents pending, I strongly believe that with the inherent heat control benefits and competitive pricing, ST10-LC909 will quickly become our flagship product."
In addition to the improved CTE achievable through the use of STABLCOR technology, the PCB manufacturer and fabricator will experience the following benefits: Easy to drill through small (8mil) holes, not abrasive to the drill bit (carbon is lubricant to the drilling); low Z-axis expansion, when compared to boards using Thermount materials; no moisture absorption issues; the PCB will act as a heat spreader, which substantially reduces hot spot; increased rigidity without increasing the weight of the board; decreased temperatures in lead-free assembly.
About Stablcor Inc.
STABLCOR® is the only provider of a thermally and electrically conductive carbon composite material which, when incorporated in printed circuit boards and substrates, controls heat, thermal expansion and increases the rigidity and strength of circuit boards without increasing the weight. The patented laminate and the processes to incorporated STABLCOR into circuit boards and substrates provide the electronics industry a cost efficient technology to produce smaller electronic products while eliminating the thermal, mechanical and reliability concerns that currently challenge the semiconductor industry. For more information about STABLCOR visit the company's website at www.stablcor.com.
THERMOUNT® is a registered trademark of the DuPont Company | STABLCOR® is a registered trademark of Stablcor, INC.
CONTACT:
Stablcor Inc.
Carol Burch
Vice President Marketing
714.524.1188 x203
(nasd) VLNC $3.16 Valence Technology Announces Operational Management Change
Wednesday, April 30 2008 - 8:00
$-0.22 (%-6.51)
AUSTIN, Texas--(BUSINESS WIRE)--
Valence Technology, Inc. (NASDAQ: VLNC) today announced that Tom Gaither, General Manager, Valence Energy Technology China, has assumed responsibilities for all Worldwide Operations following the departure of Ricky Hanna, Vice President of Worldwide Operations. Gaither, 58, will continue working from the company's Suzhou, China location and report directly to Robert L. Kanode, president and CEO of Valence Technology, Inc.
"We have full confidence in Tom, whose significant manufacturing experience has prepared him for expanded responsibilities," stated Kanode. "Since joining us in 2006, Tom has been a valued member of our operations management team. More recently, he was integral in laying the foundation for the company's recently announced manufacturing expansion plan to meet anticipated demand for its energy storage systems. Concurrent with his oversight of the expansion which remains on schedule, he will manage China manufacturing operations, supplier sourcing, and coordination of all shipment and fulfillment to our European and North American distribution centers."
Prior to joining Valence Technology, Tom served as Director of Technical Operations for Enhanced Messaging Systems in Southlake, Texas, a manufacturer of infrastructure products for the paging industry. During this period, he was responsible for establishment of the manufacturing function and the day to day operation of all aspects of product manufacturing including material procurement, outsourcing, production, quality assurance and customer support. Prior to Enhanced Messaging Systems, Tom spent 22 years with Motorola designing automation for the manufacture of cellular infrastructure equipment and two way mobile communications products.
About Valence Technology, Inc.
Valence Technology developed and markets the industry's first commercially available, safe, large-format family of lithium phosphate rechargeable batteries. Valence Technology holds an extensive, worldwide portfolio of issued and pending patents relating to its lithium phosphate rechargeable batteries, the only intrinsically safe lithium rechargeable battery. The company has its headquarters in Austin, Texas, and facilities in Las Vegas, Nevada, Mallusk, Northern Ireland and Suzhou, China. Valence is traded on the Nasdaq Capital Markets under the ticker symbol VLNC and can be found on the internet at www.valence.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including our statements that we are positioned to realize better execution, improve gross margins, continue to reduce production costs and expenses, realize a strong year in both customer orders and revenue and our financial guidance. Actual results may vary substantially from these forward-looking statements as a result of a variety of factors. Among the important factors that could cause actual results to differ are: the impact of our limited financial resources on our ability to execute on our business plan and the need to raise additional debt or equity financing to execute on that plan; our uninterrupted history of quarterly losses; our ability to service our debt, which is substantial in relationship to our assets and equity values; the pledge of all of our assets as security for our existing indebtedness; the rate of customer acceptance and sales of our products; the continuance of our relationship with a few existing customers, which account for a substantial portion of our current and expected sales in the upcoming year; the level and pace of expansion of our manufacturing capabilities; the level of direct costs and our ability to grow revenues to a level necessary to achieve profitable operating margins in order to achieve break-even cash flow; the level of our selling, general and administrative costs; any impairment in the carrying value of our intangible or other assets; our execution on our business strategy of moving our operations to Asia and our ability to achieve our intended strategic and operating goals; the effects of competition; and general economic conditions. These and other risk factors that could affect actual results are discussed in our periodic reports filed with the Securities and Exchange Commission, including our Report on Form 10-K for the year ended March 31, 2007, and the reader is directed to these statements for a further discussion of important factors that could cause actual results to differ materially from those in the forward-looking statements.
Source: Valence Technology, Inc.
(nasd) CRIS $1.40 Curis Reports First Quarter 2008 Financial Results
Wednesday, April 30 2008 - 8:00
$0.05 (%3.70)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Curis, Inc. (NASDAQ:CRIS), a drug development company focused on seeking to develop the next generation of targeted medicines for cancer treatment, today reported its financial results for the first quarter ended March 31, 2008.
"We are pleased with the compelling data steadily emanating from our programs, including the recent GDC-0449 Phase I data presented at AACR by Daniel Von Hoff, M.D., a phase I investigator," said Dan Passeri, Curis' President and Chief Executive Officer. "In addition, we are hard at work advancing our pipeline of preclinical oncology drug candidates. We have continued to progress CUDC-101 towards clinical testing and expect to file an IND in the near future and initiate a Phase I clinical trial in the middle of 2008."
For the first quarter of 2008, Curis reported a net loss of $3.4 million or ($0.05) per share, as compared to a net loss of $3.5 million or ($0.07) per share for the same period in the prior year.
Revenues for the first quarter of 2008 were $2.1 million as compared to $2.4 million for the first quarter of 2007, a decrease of $300,000, or 13%. The decrease in revenues was the result of a decrease in research and development contract revenues under collaborative arrangements, which concluded at various times beginning in March 2007, offset by an increase in license fee revenues as follows:
-- Research and development contracts revenues. Revenue under
research and development contracts was $200,000 for the first
quarter of 2008 as compared to $1.3 million for the same
period in the prior year, a decrease of $1.1 million, or 85%.
This decrease was primarily the result of the conclusion of
research funding under Curis' ongoing Wnt signaling pathway
discovery collaboration with Genentech in March 2007 and under
Curis' Hedgehog agonist collaboration with Wyeth in February
2008.
-- License fee revenues. During the first quarter of 2008,
license fee revenues were $1.9 million as compared to $1.1
million for the same period in 2007, an increase of $800,000,
or 73%. The increase is due to $1.8 million in license fee
revenue recognized during the first quarter of 2008 for the
sale and assignment of Curis' remaining BMP assets to Stryker
Corporation. This increase was primarily offset by a decrease
in the first quarter of 2008 of $900,000 in license fee
revenue recognized under Curis' Wnt signaling pathway
discovery collaboration with Genentech as compared to the same
period in the prior year.
Operating expenses for the first quarter of 2008 were $5.9 million as compared to $6.2 million for the first quarter of 2007, a decrease of $300,000, or 5%. The primary changes in research and development and general and administrative expenses are as follows:
-- Research and development. Curis' research and development
expenses increased by $200,000, or 6%, to $3.5 million for the
first quarter ended March 31, 2008 as compared to $3.3 million
for the same period in the prior year. The increase was due to
increased spending of $1.2 million on the Company's targeted
cancer programs, including its lead drug candidate, CUDC-101.
The spending on these programs was partially offset by
decreased research spending on programs under collaborations
with Genentech (Wnt), Wyeth (Hedgehog agonist) and Centocor
(BMP-7 screening).
-- General and administrative. General and administrative
expenses decreased by $500,000, or 17%, to $2.4 million for
the three months ended March 31, 2008 as compared to $2.9
million for the same period in the prior year. Legal services
decreased $400,000 during the first quarter ended March 31,
2008, primarily related to costs associated with foreign
patent applications in the prior year period. In addition,
stock-based compensation expense decreased by $100,000 in the
first quarter of 2008 as compared to the same period in the
prior year.
As of March 31, 2008, Curis' cash, cash equivalents and marketable securities totaled $35.2 million, and there were 63,314,836 shares of Curis' common stock outstanding. The Company expects that its existing cash, cash equivalents and marketable securities, provides adequate capital to reach into the fourth quarter of 2009.
In addition to its existing cash, cash equivalents and marketable securities, Curis would receive a $3.0 million dollar contingent payment from Genentech within 30 days of Genentech's initiation of a Phase II first-line metastatic colorectal cancer trial, should Genentech initiate such Phase II trial. In addition, Curis would receive another $3.0 million cash payment should Genentech initiate a Phase II trial in an undisclosed advanced epithelial solid tumor. Genentech has publicly stated that it plans to initiate the Phase II metastatic colorectal cancer trial in the first half of 2008 and that it expects to initiate the epithelial solid tumor trial in the second half of 2008.
"We expect to continue to focus our resources on the advancement of our proprietary compound CUDC-101 into clinical testing," said Mike Gray, Curis' Chief Financial Officer. "In addition, we continue to pursue collaboration opportunities with respect to one or more of our targeted cancer programs, including our multi-targeted cancer programs as well as our Hsp90 inhibitor class of compounds, and hope to announce a collaboration before the end of the year."
First Quarter and Recent Highlights
--Reported progress on clinical development of Hedgehog antagonist GDC-0449 with collaborator Genentech.
In March 2008, Genentech indicated that it plans to initiate three Phase II clinical trials of GDC-0449 in 2008, which include a trial in first-line metastatic colorectal cancer in the first half of 2008 and trials in advanced basal cell carcinoma and in an undisclosed advanced solid tumor of epithelial origin during the second half of 2008. In connection with the treatment of the first patient in each of the Phase II colorectal cancer and epithelial cancer trials, Genentech is obligated to make separate $3.0 million cash payments to Curis. As announced previously, Curis has already received a $3.0 million cash payment upon initiation of an expansion cohort of the Phase I clinical trial in advanced basal cell carcinoma in October 2007.
--Data presented from Phase I study of GDC-0449 at AACR.
In April 2008, at the American Association for Cancer Research Annual Meeting, Daniel D. Von Hoff, M.D., an investigator of the GDC-0449 Phase I study, presented clinical trial data from nine patients treated with GDC-0449 with locally advanced, multifocal and metastatic basal cell carcinoma. In five patients with metastatic basal cell carcinoma to the lungs, two patients had confirmed RECIST partial responses, two had ongoing stable disease and one had progressive disease. In four patients with clinically evaluable, locally advanced or multi-focal basal cell carcinoma, two patients exhibited complete response in subcutaneous masses by physical exam and two patients had improvement in skin lesions. Gli-1, a biomarker for Hedgehog signaling activity, was reduced in all evaluated patients. No significant toxicities were observed with GDC-0449 and no dose limiting toxicities were reached in the Phase I studies. Some patients experienced a loss of sense of taste, and there has been a small amount of hair and weight loss. Genentech has indicated that additional Phase I data, including full toxicity data, are expected to be presented at the upcoming American Society of Clinical Oncology Annual Meeting being held in Chicago, Illinois on May 30-June 3, 2008.
--Announced conclusion of Wyeth collaboration.
In March 2008, Wyeth notified Curis that it decided not to pursue its development efforts on the Hedgehog agonist program and would terminate the January 2004 collaboration agreement. Pursuant to the agreement, the collaboration will conclude on May 6, 2008. Curis is dedicated to advancing this program and is seeking a new partner to help explore the future prospects of the Hedgehog agonist as a potential therapeutic for various diseases, including in neurological, cardiovascular and bone disorders, as well as wound healing and hair growth.
Conference Call Information
Curis will hold a conference call today, April 30, 2008, at 9:00 A.M. EDT, to discuss the progress of GDC-0449, CUDC-101 and the Company's other targeted cancer programs, Curis' financial results and additional corporate activities.
To access the live conference call, please call (800) 901-5213 from the United States or Canada or (617) 786-2962 from other locations, shortly before 9:00 A.M. EDT. The conference ID number is 35236902. The conference call can also be accessed on the Curis website at www.curis.com in the Investors section. A replay will be available approximately two hours after the completion of the call through 5:00 P.M. EDT, Wednesday, May 14, 2008. To access the replay, please call (888) 286-8010 from the United States or Canada or (617) 801-6888 from other locations and reference the conference ID number 74907300.
(nasd) WPTE $1.40Lakes Entertainment, Inc. Partners with Myohionow.com, LLC to Pursue Development of Casino in Ohio
Wednesday, April 30 2008 - 8:00
$0.06 (%4.48)
MINNEAPOLIS--(BUSINESS WIRE)--
Lakes Entertainment, Inc. (NASDAQ: LACO) announced today that it has partnered with Myohionow.com, LLC to pursue the development of a first class $600 million casino resort in Clinton County, Ohio. The proposed casino resort is contingent on the voters approving a referendum in the November 4, 2008 Ohio statewide election to amend the Ohio constitution to permit the casino resort to be located in Clinton County, Ohio. MyOhioNow.com, an Ohio company founded by Dr. Brad Pressman and Rick Lertzman, is in the process of collecting 402,225 signatures as required by state law to place the referendum on the November 4, 2008 ballot.
Initial plans call for the casino to feature approximately 220,000 square feet of gaming space, including up to 5,000 slot machines, 100 table games such as Blackjack, Craps, Baccarat, Pai Gow Poker and Three and Four Card Poker, and a 20 table poker room. The proposed casino is also expected to feature up to a 1,500-room suite-hotel, multiple restaurants, entertainment bars and retail shops. Plans also include a full service destination spa, entertainment complex and championship golf course.
Under the current development plan, construction of the planned casino would likely commence within 12 - 18 months after the referendum is approved, and the casino would open approximately 18 months after construction commences. The casino is expected to employ up to 5,000 people and could generate over $200 million in gaming tax revenues that would be divided directly among all 88 Ohio counties on a per capita basis.
"This is an outstanding opportunity for Ohio," said Lyle Berman, CEO of Lakes. "We believe the project will directly benefit the people of Ohio by creating a large number of jobs in the state and also generate millions in tax revenue that will go directly to the counties, on a per capita basis, to be spent as each county wishes."
"Rick and Brad have been instrumental in communicating the benefits of the casino and gathering the signatures for the referendum," added Tim Cope, President and CFO of Lakes. "We plan on supporting their efforts through strategic advice and financial assistance that is necessary to get the referendum on the ballot, and then developing a truly first class casino resort of which all of Ohio can be proud. We have the gaming expertise and Myohio understands the people and issues of Ohio. That makes this a great partnership."
About Lakes Entertainment
Lakes Entertainment, Inc. currently has development and management or financing agreements with four separate Tribes for casino operations in Michigan, California, and Oklahoma, for a total of five separate casino sites. Lakes is currently managing the Cimarron Casino for the Iowa Tribe of Oklahoma and the Four Winds Casino Resort for the Pokagon Band of Potawatomi Indians. Lakes is also involved in other business activities, including possible development of a Company owned casino resort project in Vicksburg, Mississippi and the development of new table games for licensing to Tribal and non-Tribal casinos. The Company also owns approximately 61 percent of WPT Enterprises, Inc. (NASDAQ: WPTE), a separate publicly held media and entertainment company engaged in the creation of internationally branded entertainment and consumer products driven by the development, production and marketing of televised programming based on gaming themes, including the World Poker Tour(R) television series, the operation of an online gaming website, the licensing and sale of branded products and the sale of corporate sponsorships.
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Lakes Entertainment, Inc.) contains statements that are forward-looking, such as statements relating to plans for future expansion and other business development activities as well as other capital spending, financing sources and the effects of regulation (including gaming and tax regulation) and competition. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future and, accordingly, such results may differ from those expressed in any forward-looking statements made by or on behalf of the company. These risks and uncertainties include, but are not limited to, obtaining a sufficient number of signatures to place the Ohio casino resort project on the November 4, 2008 Ohio statewide election ballot or if the referendum is placed on that ballot, that the referendum will pass, need for current financing to meet Lakes' operational and development needs; those relating to the inability to complete or possible delays in completion of Lakes' casino projects, including various regulatory approvals and numerous other conditions which must be satisfied before completion of these projects; possible termination or adverse modification of management or development contracts; Lakes operates in a highly competitive industry; possible changes in regulations; reliance on continued positive relationships with Indian tribes and repayment of amounts owed to Lakes by Indian tribes; possible need for future financing to meet Lakes' expansion goals; risks of entry into new businesses; reliance on Lakes' management; and the fact that the WPTE shares held by Lakes are currently not liquid assets, and there is no assurance that Lakes will be able to realize value from these holdings equal to the current or future market value of WPTE common stock. There are also risks and uncertainties relating to WPTE that may have a material effect on the company's consolidated results of operations or the market value of the WPTE shares held by the company, including WPTE's significant dependence on the GSN as a current source of revenue, and the risk that GSN will not exercise its options to air seasons of the WPT series beyond Season Six; difficulty of predicting the growth of WPTE's online gaming business, which is a relatively new industry with an increasing number of market entrants; reliance on the efforts of CryptoLogic to develop and maintain the online gaming website in compliance with WPTE's business model and applicable gaming laws; the potential that WPTE's television programming will fail to maintain a sufficient audience; the risk that WPTE may not be able to protect its entertainment concepts, current and future brands and other intellectual property rights; the risk that competitors with greater financial resources or marketplace presence might develop television programming that would directly compete with WPTE's television programming; risks associated with future expansion into new or complementary businesses; the termination or impairment of WPTE's relationships with key licensing and strategic partners; and WPTE's dependence on its senior management team. For more information, review the company's filings with the Securities and Exchange Commission.
Source: Lakes Entertainment, Inc.
(nasd) AVRX $1.97Avalon Pharmaceuticals to Release First Quarter 2008 Results
Wednesday, April 30 2008 - 8:00
$0.16 (%8.84)
GERMANTOWN, Md.--(BUSINESS WIRE)--
Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced that it is scheduled to release financial results for the first quarter of 2008 on Wednesday, May 7, 2008 after the close of the U.S. financial markets. The Company will also host a conference call on Thursday, May 8, 2008 at 8:30 am Eastern Time to provide a company update and discuss the financial results for the quarter. Interested investors, analysts, members of the media and the general public can listen to the call live over the Internet or by dialing the numbers listed below.
Conference Call details:
----------------------------------------------------------------------
Dial-In: (877) 419-6597 (U.S.)
(719) 325-4858 (International)
Passcode: 4845885
Webcast: To access the call by live webcast, please visit the
Investor Relations section of our website at
http://www.Avalonrx.com. An archived version of the
webcast will be available for 30 days.
About Avalon Pharmaceuticals
Avalon is a biopharmaceutical company focused on the discovery, development and commercialization of first-in-class cancer therapeutics. Avalon's lead product candidate, AVN944, an IMPDH inhibitor, is in Phase II clinical development. Avalon also has preclinical programs to develop inhibitors of the Beta-catenin and Aurora/Centrosome pathways, discovery programs for inhibitors of the Survivin and Myc pathways and partnerships with Merck, AstraZeneca/MedImmune, ChemDiv, Medarex, and Novartis. AvalonRx(R) is the company's proprietary platform which is based on large-scale biomarker identification and monitoring, used to discover and develop therapeutics for pathways that have historically been characterized as "undruggable." Avalon is headquartered in Germantown, MD.
Source: Avalon Pharmaceuticals, Inc.
(nasd) ARTG $3.66Mobile Commerce Innovator Wins First ATG e-Commerce Ingenuity Business Plan Competition
Wednesday, April 30 2008 - 7:35
$-0.10 (%-2.66)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
ATG (Art Technology Group, Inc., NASDAQ: ARTG), the top ranked e-commerce platform and optimization services provider, today announced the winner of the first ATG e-Commerce Ingenuity Business Plan Competition.
MinuteBank was selected by the panel of judges as the $50,000 first place winner, and won over an audience of over 600 attendees as the $10,000 people's choice winner, selected by SMS voting live at the event.
As a mobile commerce (m-commerce) solution, MinuteBank plans to offer millions of mobile phone subscribers in developing nations a better way to manage their prepaid mobile phone plans. The solution is delivered as a new kind of bank account, a Personal Mobile Minute Account. This business plan focuses on a new potential market in m-commerce, whereby consumers use mobile phones to connect and transact. In emerging economies, where investment in the internet and accompanying hardware are beyond the means of both consumers and their governments, the mobile phone is fast becoming a leading medium for e-commerce.
MinuteBank founders are currently pursuing their MBAs at the UC-Berkeley Haas School of Business, and came together to fill an unmet need in the pre-paid mobile phone market, which is especially prevalent in developing nations like India.
Cliff Conneighton, ATG Senior VP of Marketing, said, "I want to congratulate MinuteBank and thank all of the other competition finalists for participating in this event. It's clear that a huge amount of thought and effort went into every one of their presentations. All the presenters have amazing things ahead of them. They are the next business leaders to watch."
Just prior to the finalist presentations, ATG e-Commerce Insight Live 2008 keynote speaker Hung LeHong, Research VP of Garntner research, spoke about the growing importance of mobile commerce, and e-commerce transactions on platforms other than PCs.
"We want to thank ATG and the participants at ATG Insight Live for giving us this opportunity. This was a really exciting event and a thrill to present," said Russell Tillitt, CEO of MinuteBank, who presented the plan. "This award is going to be so instrumental in taking MinuteBank to the next level," added Bethany Nelson, MinuteBank's COO.
ATG will be watching the development of MinuteBank and keeping track of its progress.
About ATG
ATG (Art Technology Group, Inc., NASDAQ: ARTG) provides the e-commerce platform and e-commerce optimization services that the world's most customer-conscious companies use to power their e-commerce Web sites, attract prospects, convert them to buyers and ensure their satisfaction so they become loyal, repeat, profitable customers. Our e-commerce suite is ranked the #1 current offering and #1 in strategy by the industry's most influential analyst firms, and powers more of the top 300 internet retailers than any other vendor. Our eStara brand of e-commerce optimization services - including the world's most widely used click to call offering - dramatically increase conversions and order size and enhance customer support. ATG's solutions are used by over 900 major brands, including AT&T, Best Buy, Bulgari, Coca Cola, Continental Airlines, CVS, Dell, Diane von Furstenberg, DirecTV, eLuxury, El Corte Ingles, Expedia, France Telecom, Harvard Business School Publishing, Hewlett-Packard, Hilton, HSBC, Intuit, Jenny Craig, Louis Vuitton, Macy's, Mercedes Benz, Meredith, Microsoft, Neiman Marcus, New York & Company, NutriSystem, OfficeMax, PayPal, Philips, Procter & Gamble, Sears, Sony, Symantec, Target, T-Mobile, Tommy Hilfiger, Urban Outfitters, Verizon, Viacom, Vodafone and Walgreens.
For more information about ATG, please visit www.atg.com.
(C) 2008 Art Technology Group, Inc. ATG and Art Technology Group are registered trademarks, and ATG Wisdom is a trademark of Art Technology Group, Inc. All other product names, service marks, and trademarks mentioned herein are trademarks of their respective owners.
This press release contains forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks and uncertainties that may cause ATG's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Important risk factors affecting ATG's business generally may be found in its periodic reports and registration statements filed with the Securities and Exchange Commission at www.sec.gov. Risk factors related to the subject matter of this press release include the possibility that the ATG product deployment will not be successful, on time or significantly enhance the user's Internet experience or will not increase customer revenue across brands; that those customers leveraging ATG will not have the opportunity to increase revenue and decrease future costs; the need to adapt to rapid changes so products do not become obsolete; the possibility of errors in ATG's software products; the possibility that the solution will not make customer implementations faster or more flexible or permit the customer to meet its customer-facing or infrastructure requirements; that the ATG product will not continue to be integrated with third party applications servers or will not support all Web services enabled systems; that ATG's product strategy may change in the future; and the risks and costs of intellectual property litigation. ATG undertakes no obligation to update any of the forward-looking statements after the date of this press release.
Source: Art Technology Group, Inc.
(nasd) AEZS $1.22 AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan
Wednesday, April 30 2008 - 7:30
$-0.02 (%-1.61)
QUEBEC CITY, April 30 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that Prof. Frans M.J. Debruyne, M.D., Ph.D., Chairman and CEO of Andros Men's Health Institutes in The Netherlands, won the award for Best Poster Presentation in a Poster Session at the 23rd Annual European Association of Urology Meeting, which was held March 26-28, 2008 in Milan, Italy. Titled "LHRH antagonist cetrorelix for symptomatic BPH: Prolonged improvement beyond end of treatment in placebo-controlled trials." FMJ Debruyne, A.A. Gres, A. Bantschev, M. Tzvetkov, K. Grdovic, the poster referred to previously disclosed results from two Phase 2 trials with cetrorelix in benign prostatic hyperplasia (BPH), which showed a prolonged duration of effect extending far beyond the end of the short-term treatment course.
Prof. Jurgen Engel, Ph. D., Executive Vice President, Scientific Affairs at AEterna Zentaris commented, "We would like to congratulate Professor Debruyne for this prestigious award which acknowledges his significant contribution to the quality and achievements of our drug development program with cetrorelix in BPH. The data observed in these Phase 2 trials warranted our current extensive Phase 3 program with cetrorelix in this same indication and we look forward to presenting the results in Q3 2009, as stated previously. We believe cetrorelix could provide a novel, efficient, convenient and safe treatment for the millions of men with BPH."
THE POSTER
Introduction and Objectives
Preliminary studies indicated prolonged, unmaintained improvement in signs and symptoms of BPH after short courses of cetrorelix. Two placebo-controlled trials investigated two formulations of cetrorelix to determine the extent and duration of symptomatic improvement and to select the interval between courses for an intermittent treatment scheme.
Trial Design
Trial-A compared 3 regimens of subcutaneous cetrorelix acetate with placebo (35 patients/group): 5mg x 4, 7 days apart; 10mg x 4, 7 days apart; and 10mg x 2, 14 days apart.
Trial-B compared 4 regimens of intramuscular cetrorelix pamoate with placebo (30 patients/group, 14 days between doses): 30mg x 2; 30mg x 3; 60mg and 30mg; 60mg x 2. Patients were followed up for 20 and 28 weeks after the first dose in Trial-A and B, respectively. International Prostate Symptom Score (I-PSS) primary endpoint was assessed in 4-weekly intervals; other endpoints included uroflow, prostate size, and testosterone levels.
Results
In both trials, 4 weeks after first dose, all regimens showed a statistically significant reduction in I-PSS from baseline; at week 12, the difference from placebo was statistically significant for all dosage regimens except the 30mg x 2 in Trial-B (Trial-A: p<0.05; Trial-B: p <0.001). Generally, the improvement in I-PSS, which tended to be better in the higher dosage groups of Trial-B (reduction of 5-7 points, i.e. 30%-40%), was maintained throughout the follow-up period and was paralleled by an improvement in uroflow. A slight, dose-dependent reduction in prostate size was noticed in both trials. All dosage regimens tested were well tolerated, and none were associated with sexual side effects.
Conclusions
In both studies, a prolonged duration of effect extending far beyond the end of the short-term treatment course was observed. For the long-term management of BPH patients, the results from both studies support a 6-month interval between subsequent treatment courses.
About Cetrorelix
Cetrorelix is part of AEterna Zentaris' LHRH antagonist therapeutic approach that has demonstrated in Phase 2 studies to provide fast and long-lasting relief of BPH symptoms while being well tolerated, with a low incidence of sexual side effects. Both BPH studies of cetrorelix presented in Milan were chaired by Prof. Frans M.J. Debruyne, M.D., Ph.D., former President of EAU, now Chairman and CEO of Andros Men's Health Institutes in The Netherlands.
Cetrorelix peptide-based drugs were developed by the Company in cooperation with Nobel Prize winner Prof. Andrew Schally, currently of the U.S. Veterans Administration in Miami.
Cetrorelix acetate is marketed under the brand name Cetrotide(R), the first LHRH antagonist approved for therapeutic use as part of in vitro fertilization programs (controlled ovarian stimulation/assisted reproductive technologies) in Europe, the U.S. and Japan. It was launched on the market through Serono (now Merck Serono) in the United States, Europe and in several other countries, as well as in Japan through Shionogi.
About the Cetrorelix Phase 3 Program in BPH
Cetrorelix pamoate is being studied in three Phase 3 trials which will include approximately 1,500 men with symptomatic BPH in the United States, Canada and Europe. One Phase 3 efficacy trial, primarily in the United States and Canada and with additional sites in Europe, involves approximately 600 patients (which are fully enrolled) and is being led by Herbert Lepor, M.D., Professor and Martin Spatz Chairman of Urology, New York University School of Medicine, New York. In the trial, patients enter a no-treatment run-in observation period to confirm severity and stability of voiding symptoms based on the International Prostate Symptom Score (I-PSS). Patients are then randomly allocated to cetrorelix or placebo in a double-blind fashion. Patients are administered cetrorelix by intra-muscular (IM) injection at Week 0, 2, 26 and 28 and are followed up to Week 52. Then, in an open-label extension, patients will receive cetrorelix by IM injection at Week 52, 54, 78 and 80 will be followed up to Week 90.
A second, similarly designed multi-center Phase 3 efficacy study, being led by Prof. Frans M.J. Debruyne, M.D., Ph.D., from The Netherlands, will enroll approximately 400 patients in Europe. The third Phase 3 trial scheduled to start shortly, is an open-label, single-armed multi-center safety study involving approximately 500 patients in both North America and Europe, and is being led by Joel Kaufman, M.D., Associate Clinical Professor of Urology, University of Colorado School of Medicine, Denver, Colorado, and Urology Research Options, Aurora, Colorado.
The primary endpoint for both North American and European efficacy studies is the change in I-PSS between baseline and Week 52. Other efficacy endpoints include additional measures of BPH-symptom progression and the need for BPH-related surgery. Safety endpoints include changes in sexual function. Other important endpoints include plasma changes in levels of testosterone, and assessment of other adverse events.
The cetrorelix Phase 3 program is based on comprehensive clinical practice guidelines to ensure quality control, including input from expert advisors on study design, publishing results in peer-reviewed journals and discussion of the studies with regulatory agencies.
Benign Prostatic Hyperplasia
Benign prostatic hyperplasia (BPH) is one of the most common diseases of aging men - affecting more than 20 million men in the United States - but its etiology is far from being completely understood. Data from ongoing research suggest BPH and its associated lower urinary tract symptoms (LUTS) are more complex conditions than once thought. While previous research on BPH etiology tended to focus on testosterone and other hormones, more recent research suggests other factors may play a greater role in the development of BPH and LUTS - including inflammation, various growth factors, and adrenoreceptors.
BPH-associated LUTS include frequent urination and/or urgent need to urinate, waking at night to urinate (nocturia), difficulty starting urination and/or weak urinary stream, and feeling that the bladder is not completely empty after urination. While current therapies provide some efficacy in BPH they are often associated with troublesome sexual side effects.
About AEterna Zentaris Inc.
AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization.
News releases and additional information are available at www.aezsinc.com.
Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are requested by a governmental authority or applicable law.
SOURCE AETERNA ZENTARIS INC.
(nasd) MEDE $1.53 MEDecision Enters Agreement With Blue Cross and Blue Shield of Florida
Wednesday, April 30 2008 - 7:30
$0.19 (%14.18)
WAYNE, Pa.--(BUSINESS WIRE)--
MEDecision, Inc. (Nasdaq: MEDE), a leading provider of collaborative health care management solutions, today announced that it has entered into an agreement to deliver its Alineo(TM) Collaborative Health Care Management platform to Blue Cross and Blue Shield of Florida (BCBSF).
"We are very pleased to work with a health plan known as a leader," said MEDecision Founder and CEO David St.Clair. "Alineo will provide BCBSF with a simplified, smart and state-of-the-art solution that represents some of the most advanced technology of its kind currently available."
Alineo is a collaborative health care management platform for addressing case management, disease management and utilization management. Through an innovative, member-centric approach, it analyzes, applies and automates payer-driven best practices. Alineo enables health plans to streamline operational efficiencies, reduce waste and increase care quality by helping them optimally manage risk and compliance, enhance business agility and control costs.
BCBSF will implement Alineo in a two-phase process that will begin immediately and continue through 2009. MEDecision introduced Alineo on January 15 as its completely re-architected collaborative health care management platform comprising a series of individual components, including: Alineo Reporting, Alineo Correspondence, Alineo Automated Approvals, Alineo Clinical Criteria, Alineo Clinical Programs, Alineo Clinical Intelligence, Alineo Clinical Summaries and Alineo Care Management Analytics.
For more information, please visit www.MEDecision.com.
About MEDecision
MEDecision offers collaborative health care management solutions that provide a simplified and smart way to manage the health of members and member populations which can improve the quality and affordability of care. Based on state-of-the-art technology, MEDecision's solutions include Alineo(TM), a collaborative health care management platform for managing case, disease and utilization management and Nexalign(TM), a collaborative health care information exchange service. MEDecision believes that, in the aggregate, its health care payer customers insure or manage care for approximately one in every six people in the U.S. with health insurance. For more information, please visit www.MEDecision.com.
MEDecision is a trademark of MEDecision, Inc. The MEDecision logo and product names are also trademarks or registered trademarks of MEDecision, Inc. Other product and brand names are trademarks of their respective owners.
MEDE-G
Source: MEDecision, Inc.
(nasd) NTII $2.34Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
Wednesday, April 30 2008 - 7:01
$-0.03 (%-1.27)
EMERYVILLE, Calif., April 30 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it has received approximately $2.0 million from Merz Pharmaceuticals GmbH (Merz) for sales by Merz and its marketing partners of Memantine for the treatment of moderate-to-severe Alzheimer's disease during the quarter ended December 31, 2007. Under an exclusive marketing agreement, NTI currently receives quarterly royalty payments on certain sales of Memantine by Merz and its marketing partners.
About Neurobiological Technologies, Inc.
Neurobiological Technologies, Inc, (Nasdaq: NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in phase 3 clinical testing as a novel investigational drug for treating acute ischemic stroke. Viprinex has multiple mechanisms of action and is specifically designed to double the time period that patients can be treated after the onset of a stroke. Acute ischemic stroke is one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. NTI's pipeline also includes a phase 3 investigational drug for brain swelling and other drug candidates in early-stage development for Alzheimer's and Huntington's diseases.
SOURCE Neurobiological Technologies, Inc.
(nasd) CRWS $3.44 Crown Crafts Infant Products, Inc. Signs Licensing Agreement for Its Kimberly Grant Brand With C.R. Gibson, LLC
Wednesday, April 30 2008 - 7:00
$0.04 (%1.18)
COMPTON, Calif., April 30 /PRNewswire-FirstCall/ -- Crown Crafts Infant Products, Inc., a Crown Crafts, Inc. company (the "Company") (Nasdaq: CRWS), today announced it has formalized a licensing agreement for its Kimberly Grant brand with C.R. Gibson, LLC. This new arrangement will mark an expansion of the Kimberly Grant brand beyond its roots as an infant bedding and nursery decor program.
C.R. Gibson will introduce a line of products including baby books, photo albums, keepsake boxes, calendars, brag books, growth charts and gift bags featuring several of the most popular designs from Kimberly Grant. Under the license agreement, these new products may be sold through a variety of retail channels, including the gift and specialty stores channel.
"We are excited to see the Kimberly Grant brand grow outside the infant bedding category. Kimberly Grant is a brand with a design aesthetic that easily translates to a wide variety of infant products," noted Nanci Freeman, President and CEO of Crown Crafts Infant Products, Inc. "We are pleased to be partnering with C.R. Gibson, a well-respected and creative company."
About Crown Crafts, Inc.
Crown Crafts Infant Products is a Crown Crafts, Inc. company. Crown Crafts is America's largest producer of infant and toddler bedding, bibs and bath items. The Company's products include licensed and branded collections as well as exclusive private label programs for certain of its customers.
About C.R. Gibson, LLC
C.R. Gibson, LLC, based in Nashville, Tennessee, is a leading designer, marketer and distributor of memory books, stationery, journals, paper tableware, photo albums, scrapbooks and other gift items that commemorate life's celebrations. C.R. Gibson's products are available at more than 10,000 gift retailers in the United States, Canada, and the United Kingdom.
SOURCE Crown Crafts Infant Products, Inc.
(nasd) EVOL $2.223Evolving Systems Sets Date for 2008 1st Quarter Release and Conference Call
Wednesday, April 30 2008 - 7:00
$0.073 (%3.40)
ENGLEWOOD, CO -- (MARKET WIRE) -- 04/30/08 -- Evolving Systems, Inc. (NASDAQ: EVOL), a leading provider of software solutions and services to the wireless, wireline and IP carrier market, today announced it will release its 2008 first quarter financial results after the market closes on May 8, 2008, and conduct a conference call the same day at 3:00 p.m. Mountain Time.
The call-in numbers for the conference call are 1-888-680-0894 for domestic toll free and 617-213-4860 for international callers. The passcode is 73636226.
Participants may pre-register for the call by clicking the following link:
https://www.theconferencingservice.com/prereg/key.process?key=PPK7K483T
Pre-registration provides quick access to the call by bypassing the operator upon connection. Upon pre-registration, participants will be provided a pin number to enter when dialing in and will avoid hold times. Pre-registration is not mandatory.
A telephone replay will be available through May 22, 2008, and can be accessed by calling 1-888-286-8010 or 617-801-6888, passcode 54260693.
To access a live Webcast of the call, please visit Evolving Systems' website at www.evolving.com. A replay of the Webcast will be accessible at that website through May 22, 2008.
About Evolving Systems®
Evolving Systems (NASDAQ: EVOL) is a worldwide provider of software and services to telecommunications carriers, with 70 network operators in 45 countries. The Company's software offerings address Activation, Dynamic SIM Allocation, Number Portability, Number Management and Mediation. These solutions help carriers deliver an improved customer experience, shorter time-to-market and lower cost of rendering value-added services. With an expanding solutions portfolio, global sales and support, onshore/offshore development, and a focus on emerging markets, Evolving Systems is well positioned for growth. Founded in 1985, the Company has headquarters in Englewood, Colorado, with offices in the United Kingdom, Germany, India and Malaysia.
CONTACTS:
Investor Relations
Jay Pfeiffer
Pfeiffer High Investor Relations, Inc.
303.393.7044
Email Contact
(nasd) NCST $1.039Interleukin Genetics Appoints Eliot M. Lurier Chief Financial Officer
Wednesday, April 30 2008 - 7:00
$0.02 (%1.96)
WALTHAM, Mass., April 30 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (Amex: ILI), today announced that it has appointed Eliot M. Lurier, CPA, as its Chief Financial Officer.
Lewis H. Bender, Chief Executive Officer of Interleukin Genetics, Inc., commented on the appointment, "Eliot is an innovative and experienced senior financial executive with an entrepreneurial spirit and a proven record of achievement in managing growth for publicly traded companies. The addition of Eliot to the senior management team provides financial management and operational skills that we need to develop and grow our business."
Mr. Lurier, age 50, has more than 25 years of financial management experience, primarily in the life sciences industry. Prior to joining Interleukin Genetics, he was Vice President, Finance and Administration and Chief Financial Officer of Nucryst Pharmaceuticals (Nasdaq: NCST, TSX: NCS), where he successfully completed a $45 million IPO within 6 months of joining the company and was responsible for SEC reporting and the implementation of Sarbanes-Oxley requirements. Previously, he served as Chief Financial Officer and Chief Operating Officer for Bridge Pharmaceuticals, Inc., where he established all policies for managing business operations.
Mr. Lurier commented, "I am very excited about the opportunity to join Interleukin Genetics. The Company is well positioned to become a leading provider of preventive consumer products and genetic tests for sale to the emerging personalized health market. I look forward to helping the Company communicate the value of such tests to the investment community."
Prior to joining Bridge Pharmaceuticals, Inc., Mr. Lurier held a number of senior-level financial positions including Chief Financial Officer of Admetric Biochem, Inc., and Chief Financial Officer, Treasurer and Vice President of Finance of Ascent Pediatrics, Inc., a publicly traded pharmaceutical company.
Earlier in his career, Mr. Lurier was Senior Accountant at Coopers and Lybrand. He earned a B.S. in Accounting from Syracuse University and is a Certified Public Accountant in Massachusetts.
About Interleukin Genetics
Interleukin Genetics, Inc. (Amex: ILI) is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin Genetics has developed and commercialized genetic tests for risk assessment of coronary artery disease, periodontal disease, and general nutrition. The Company currently offers an array of Nutraceuticals and OTCeuticals(R), including Ginkoba(R), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers. Interleukin is headquartered in Waltham, MA. For more information about Interleukin and its ongoing programs, please visit www.ilgenetics.com.
Certain statements contained herein are "forward-looking" statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward- looking statements include, but are not limited to, the risk of market acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, and those risks and uncertainties described in our annual report on Form 10-K for the year ended December 31, 2007, filed with the Securities and Exchange Commission, our quarterly reports on Form 10-Q and other filings made by us with the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.
SOURCE Interleukin Genetics, Inc.
(nasd) ALTI $2.33 Altair Nanotechnologies Announces First Quarter 2008 Financial Results Conference Call
Wednesday, April 30 2008 - 7:00
$0.13 (%5.91)
RENO, Nev.--(BUSINESS WIRE)--
Altair Nanotechnologies Inc. (Nasdaq: ALTI) announces that it will hold a conference call to discuss financial results for the first quarter ended March 31, 2008. The call is scheduled for Wednesday, May 7, 2008 at 11:00 a.m. Eastern Daylight Time (EDT). Shareholders and members of the investment community are invited to participate in the conference call.
The conference call dial-in number for both U.S. and international callers is 719-785-9446. Please dial in to the conference five minutes before the call is scheduled to begin. Ask the operator for the Altair Nanotechnologies call.
An audio replay of the conference call will be available from 2:00 p.m., May 7 through 11:59 p.m. EDT, May 14, 2008. It can be accessed by dialing 719-457-0820 and entering conference number 5546966.
Additionally, the conference call and replay are available online, and can be accessed by visiting Altair Nanotechnologies' web site, www.altairnano.com.
ABOUT ALTAIR NANOTECHNOLOGIES INC.
Altairnano is an innovator and supplier of advanced novel, ceramic nanomaterials. Altairnano's leading edge scientists are complemented by a seasoned management team with substantial experience in commercializing innovative, disruptive technologies. The company has developed nanomaterials for the alternative energy, life sciences and performance materials markets based on its proprietary manufacturing process. This process also provides the foundation for its innovative AHP pigment process. For more information visit: www.altairnano.com.
Source: Altair Nanotechnologies Inc.
(nasd) COIN Converted Organics Inc. Appoints William A. Torello, Ph.D. as Director of Product Research and Development
Wednesday, April 30 2008 - 7:00
$0.0 $0.0 (%0.0)
BOSTON--(BUSINESS WIRE)--
Converted Organics Inc. (NASDAQ:COIN) announced today that it has appointed William A. Torello, Ph.D., as its new Director of Product Research and Development. Mr. Torello, who holds three patents in organic fertilizers and biological control products and methodology, has over three decades of expertise in all facets of plant and agronomic product research, including the development and evaluation of organic fertilizers, organic amendments, turfgrass species and varieties, and organic pest control materials.
"Bill's very impressive breadth of industry and academic experience make him exceptionally well-qualified to direct Converted Organics' cutting-edge research and development program," said Edward J. Gildea, President and CEO of Converted Organics Inc. "His expertise in turfgrass management and organic product development will enable him to make a tremendous contribution to the Company and accelerate our product pipeline."
"Joining Converted Organics is significant to me on both a professional and a personal level," said Bill Torello. "Since Converted Organics' core technology is focused on the rapid thermal composting of food waste, the global growth potential for this waste solution and the unique organic fertilizer products it generates is phenomenal. The fact that this technology also reduces land fill deposits and corresponding methane and carbon dioxide emissions fulfills my desire to see a rapid solution to an important environmental problem."
Dr. Torello, age 57, is a former Professor Emeritus in the Department of Plant and Soil Sciences at the University of Massachusetts, Amherst, where he directed the university's turfgrass management, research, teaching and outreach programs. In this capacity, Mr. Torello developed an extensive field and laboratory research program that encompassed turfgass variety evaluations, fertilizer and organic amendment trials, soil nitrogen fate, turfgrass biotechnology, and environmental stress projects. He also developed the first self-contained golf green system to recycle fertilizer and irrigation water, while eliminating any possible chemical contaminations.
Dr. Torello is also the founder and former Executive Vice President of EcoOrganics, Inc., a product development, testing and marketing company that patented a novel, new species of bacteria with strong anti-fungal activity, as well as a unique delivery system of bacteria and organic media via porous ceramic particles. Mr. Torello is the Senior Editor of the Journal of Turfgrass Management, as well as a widely published author, with over 100 agronomy-related scientific and industry publications to his credit. He is also the former President of Professional Turfgrass Consulting, a private consulting company focused upon the professional sport, lawn care and private estate markets.
About Converted Organics Inc.
Converted Organics (NASDAQ:COIN), based in Boston, MA, is dedicated to producing valuable all natural, organic soil amendment or fertilizer products through food waste recycling. The company uses proven, state-of-the-art technologies to create a product that helps grow healthier food and improve environmental quality. Converted Organics plans to sell and distribute its environmentally-friendly fertilizer products in the retail, turf management, and agribusiness markets.
Converted Organics' fertilizer products will be produced in both a dry pellet and liquid concentrate. Converted Organics' products have been tested in numerous field trials for more than a dozen crops with the result that, on average, the net value of the farmer's crop increased 11-16%, depending on the particular crop and product application. This is due, in part, to the disease suppression characteristics of the product, which reduce or eliminate the need for other costly, often toxic, crop protection applications. Increased use of nitrogen in commercial agriculture and turf grass applications, such as golf courses, has reduced the soil's ability to absorb nitrogen and other nutrients. Using the products produced by Converted Organics helps restore the soil by replenishing these micronutrients. This reduces the amount of nitrogen required in a virtuous cycle that benefits from long-term use. As a result, use of the product will reduce chemical run-off to streams, ponds and rivers, an objective with significant long term benefits to the environment.
The products have a long shelf life compared to many other organic fertilizers. In a number of lab and field trials, the liquid product has been shown to be effective in mitigating powdery mildew, a leaf fungus that effects most plants and grasses and restricts the flow of water and nutrients to the plant. The Company's fertilizer products can be used on a stand-alone basis or in combination with more traditional fertilizers and crop protection products. Converted Organics expects to benefit from increased regulatory focus on organic waste processing and on environmentally-friendly growing practices.
This press release contains forward-looking statements that are subject to risks and uncertainties. These forward-looking statements include information about possible or assumed future results of our business, financial condition, liquidity, results of operations, plans and objectives. In some cases, you may identify forward-looking statements by words such as "may," "should," "plan," "intend," "potential," "continue," "believe," "expect," "predict," "anticipate" and "estimate," the negative of these words or other comparable words. These statements are only predictions. One should not place undue reliance on these forward-looking statements. The forward-looking statements are qualified by their terms and/or important factors, many of which are outside the Company's control, involve a number of risks, uncertainties and other factors that could cause actual results and events to differ materially from the statements made. The forward-looking statements are based on the Company's beliefs, assumptions and expectations of our future performance, taking into account information currently available to the Company. These beliefs, assumptions and expectations can change as a result of many possible events or factors, including those events and factors described in "Risk Factors" in the prospectus, not all of which are known to the Company. Neither the Company nor any other person assumes responsibility for the accuracy or completeness of these statements. The Company will update the information in this press release only to the extent required under applicable securities laws. If a change occurs, the Company's business, financial condition, liquidity and results of operations may vary materially from those expressed in the aforementioned forward-looking statements.
COIN-G
Source: Converted Organics Inc.
(nasd) NSUR $3.78 Insure.com, Inc. Reports First Quarter 2008 Financial Results
Wednesday, April 30 2008 - 6:30
$-0.01 (%-0.26)
DARIEN, Ill., April 30 /PRNewswire-FirstCall/ -- Insure.com, Inc. (Nasdaq: NSUR), the only place on earth where you can get auto, life, health, home and business insurance quotes from over 100 leading companies and have the freedom to buy from the company of your choice, today announced financial results for the first quarter ended March 31, 2008.
Financial Results
Insure.com reported revenues of $4.0 million for the first quarter of 2008, a decrease of 5.6 percent from revenues of $4.2 million for the same quarter of 2007. Net loss for the quarter was $512,000, or $0.07 per share, compared to a loss of $882,000, or $0.12 per share, for the first quarter of 2007.
"Insure.com achieved a narrowed net loss in a difficult quarter for the life insurance market in general," said Robert Bland, chairman and CEO. "During the quarter, we successfully launched our new Remote Agent program with 75 independent agencies. These agencies will receive leads from us and provide local life insurance brokerage services to those Insure.com shoppers who may wish to buy insurance locally. Independent research shows that approximately 90 percent of life insurance shoppers still buy their life insurance through local agents and brokers, even after they research life insurance prices online. We are excited about leveraging our technology and services into this large market segment, which could generate wholesale brokerage commissions for us as a new revenue stream."
"We have been working on being more efficient with the life insurance leads we receive," stated Phil Perillo, chief financial officer. "As a result, we have been able to reduce sales and marketing expenses to 32% of revenue from 42% in the first quarter of last year. Our operational priority going forward will be to strive to improve the sales efficiency of our in-house agent force, selectively add to the in-house agent force and to expand our new Remote Agent program, all of which are designed to maximize revenue from our inbound lead flows."
Insure.com has a strong balance sheet with no debt. Cash and investments in marketable securities totaled $10.7 million at March 31, 2007.
Depreciation and amortization charges were $207,000 for the first quarter of 2008 compared to $195,000 for the first quarter of 2007.
Stockholders' equity amounted to $18.7 million at March 31, 2008, as compared to $19.2 million at December 31, 2007.
Insure.com has a stock repurchase plan in place. During the first quarter of 2008, the Company repurchased 7,750 shares and has been authorized by its board to repurchase up to 592,000 additional shares in the open market or in negotiated transactions.
About Insure.com
Originally founded in 1984 as Quotesmith Corporation, Insure.com owns and operates a comprehensive consumer information service and companion insurance brokerage service that caters to the needs of self-directed insurance shoppers. Visitors to the Company's flagship Web site, http://www.insure.com, are able to obtain free, instant car insurance quotes, instant life insurance quotes, home, business and health insurance quotes from leading insurers and have the freedom to buy online or by phone from any company shown. Insure.com also plays home to over 2,000 originally authored articles on various insurance topics and also provides free insurance decision-making tools that are not available from any other single source. Insure.com generates revenues from receipt of industry-standard commissions, including back-end bonus commissions and volume-based contingent bonus commissions that are paid by participating insurance companies. We also generate advertising revenues from the sale of Web site traffic to various third parties. Shares of the Company's common stock trade on the Nasdaq Capital Market under the symbol NSUR.
Cautions about Forward-Looking Statements
This announcement may contain forward-looking statements that involve risks, assumptions and uncertainties pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. This announcement also contains forward-looking statements about events and circumstances that have not yet occurred and may not occur. These forward-looking statements are inherently difficult to predict. Expressions of future goals and similar expressions including, without limitation, "intend," "may," "plans," "will," "believe," "should," "could," "hope," "expects," "expected," "does not currently expect," "anticipates," "predicts," "potential" and "forecast," reflecting something other than historical fact, are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. Investors should be aware that actual results may differ materially from the results predicted and reported results should not be considered an indication of future performance. Reported Web site activity and/or quotes are not necessarily indicative of any present or future revenue. The Company will not necessarily update the information in this press release if any forward-looking statement later turns out to be inaccurate. Potential risks and uncertainties include, among others, concentration of common stock holdings, general price declines within the life insurance industry, unpredictability of future revenues, potential fluctuations in quarterly operating results, competition, the evolving nature of its business model, possible write down of intangible assets and goodwill, risks associated with capacity constraints, management of growth and potential legal liability arising out of misuse, breach of confidentiality or error in the handling of confidential customer information. More information about potential factors that could affect the Company's financial results are included in the Company's Annual Report on Form 10-K for the year ended December 31, 2007 which is on file with the United States Securities and Exchange Commission.
INSURE.COM, INC.
STATEMENT OF OPERATIONS
(In thousands, except per share data)
(Unaudited)
Quarter Ended
March 31, March 31,
2008 2007
Revenues:
Commissions and fees $3,968 $4,202
Expenses:
Selling & marketing 1,281 1,775
Operations 2,235 2,144
General & administrative 872 1,059
Depreciation & amortization 207 195
Total expenses 4,595 5,173
Operating loss (627) (971)
Investment income 115 89
Net loss $(512) $(882)
Net loss per common share,
basic and diluted $(0.07) $(0.12)
Weighted average common
shares and equivalents
outstanding, basic and
diluted 7,281 7,301
SELECTED BALANCE SHEET DATA
(In thousands)
March 31, December 31,
2008 2007
Cash and equivalents $2,952 $2,072
Investments 7,711 8,941
Commissions receivable 3,087 3,263
Intangibles and goodwill 5,025 5,148
Other assets 1,705 1,515
Total assets $20,480 $20,939
Total current liabilities $1,754 $1,695
Total stockholders' equity 18,726 19,244
Total liabilities & stockholders' equity $20,480 $20,939
SOURCE Insure.com, Inc.
(nasd) MOVE $3.28 Move and REALTOR.com(R) Lead Campaign for Fresher Listings
Wednesday, April 30 2008 - 6:00
$-0.04 (%-1.20)
LOS ANGELES, April 30 /PRNewswire-FirstCall/ -- One-third of REALTOR.com's 4.4 million property listings -- over 1.55 million homes for sale -- are updated every fifteen minutes, delivering the freshest, most current collection of real estate listings on the world wide web. This means agents and brokers with listings on REALTOR.com can give their clients the edge in finding their next home by delivering reliable information on new listings, price reductions, expanded descriptions, and new photos.
"In an ever-changing market, people searching stale listings can easily lose their dream homes to competing buyers," said Rei Mesa, president and COO of Prudential Florida WCI Realty. "Having the freshest listings available gives them a competitive edge, helps them stay current with price changes, bid and price effectively, and negotiate the best deals with clarity and confidence. Move.com and REALTOR.com have done a tremendous job increasing the quantity and freshness of their real estate listings."
According to a June 2007 study by dVOC Insights LLC, home buyers believe the currency of listings to be an important factor in choosing a website to search for a home. Because one in three home-buyers look at listings daily, according to the same study, consumer interest in having access to the freshest most frequently updated listings is justified.
At program inception in August 2007, 37 multiple listing services (MLS) initially pushed fifteen-minute updates to REALTOR.com on 500,000 listings. Today, 203 MLS systems now feed REALTOR.com updates every fifteen minutes on 1.55 million listings, while another 2 MLS's provide updates every four hours and 180 MLSs feed 438,000 listings twice daily to REALTOR.com. Move, Inc., which operates the official website of the National Association of REALTORS, continues to encourage more multiple listing services to provide refreshed feeds to the industry leader four times an hour.
REALTOR.com President Errol Samuelson spearheaded the company's 15-minutes fresh update campaign last year, believing the currency of listings to be critical to consumers especially during challenging real estate markets.
"On average about 13,600 homes(1) are sold in America every day and roughly the same number go up for sale on the nation's 900 multiple listing services," Samuelson said. "Tens of thousands more listings have price changes or updated information that could change the property's appeal to prospective buyers. The most sophisticated tools for searching and analyzing listings are only as good as the freshness of the data. REALTOR.com is committed to providing real estate professionals with an edge in providing their prospects and clients with relevant and vital information."
Samuelson goes on to explain that if consumers are looking at a database of information that's 24-hours old, they may miss out on opportunities or make very costly decisions.
To help consumers stay up-to-date on listing information and opportunities, REALTOR.com keeps buyers informed about listing updates by sending emails or RSS alerts when new listings match a consumer's saved search criteria or when an important change, such as a price adjustment, is made. Later this year, listings on REALTOR.com will feature a time stamp to tell consumers exactly when a listing was last updated.
"At REALTOR.com, consumers can search with confidence that they're looking at listings fresher than those on any other site," Samuelson said. "REALTOR.com and Move are committed to leveraging the latest technology to reinforce our position as the trusted leader and most-searched site in real estate."
ABOUT REALTOR.COM
REALTOR.com(R), where the world shops for real estate online, is operated by Move, Inc., (Nasdaq: MOVE) and is the official Web site of the National Association of REALTORS. Ranked as the #1 homes-for-sale site, REALTOR.com currently offers potential home buyers access to over four million property listings, as well as the most brokers and agents. It also provides REALTORS and the home sellers they represent with the Internet's largest real estate marketplace, reaching more than 6.2 million consumers in March 2008(1). Agents and companies have the power to customize REALTOR.com resources to maximize their brand and productivity.
REALTOR(R) and REALTOR.com(R) are registered trademarks of the NATIONAL ASSOCIATION OF REALTORS(R). REALTOR(R) is a federally registered collective membership mark, which identifies a real estate professional who is a Member of the NATIONAL ASSOCIATION OF REALTORS(R) and subscribes to its strict Code of Ethics. All other trademarks appearing above are the property of Move, Inc., or of their other respective owners.
ABOUT MOVE, INC.
Move, Inc. (Nasdaq: MOVE) is the leader in online real estate with 9.4 million(2) monthly visitors to its online network of websites. Move, Inc. operates: Move.com(R), a leading destination for information on new homes and rental listings, moving, home and garden and home finance; REALTOR.com, the official Web site of the National Association of REALTORS(R); Welcome Wagon(R); Moving.com; SeniorHousingNet(TM); and TOP PRODUCER(R) Systems. Move, Inc. is based in Westlake Village, California, and employs more than 1600 individuals throughout North America. For more information: http://www.move.com.
(1) NAR Existing Home Sales Report February 2008
(2) comScore March 2008
This press release may contain forward-looking statements, including information about management's view of Move's future expectations, plans and prospects, within the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other factors which may cause the results of Move, its subsidiaries, divisions and concepts to be materially different than those expressed or implied in such statements. These risk factors and others are included from time to time in documents Move files with the Securities and Exchange Commission, including but not limited to, its Form 10-Ks, Form 10-Qs and Form 8-Ks. Other unknown or unpredictable factors also could have material adverse effects on Move's future results. The forward-looking statements included in this press release are made only as of the date hereof. Move cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, Move expressly disclaims any intent or obligation to update any forward-looking statements to reflect subsequent events or circumstances.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080213/MOVEINCLOGO)
SOURCE Move, Inc.
(nasd) ATSI $1.77 ATS Medical Announces First ''Frontiers in Cryoablation'' Symposium
Wednesday, April 30 2008 - 6:00
$0.04 (%2.31)
MINNEAPOLIS, April 30 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today announced the first Frontiers in Cryoablation Symposium to be held at the American Association for Thoracic Surgery Annual Meeting in San Diego. The symposium is the first in a series of meetings intended to further the evolution and direction for cryoablation therapy, a treatment for atrial fibrillation. Dr. James L. Cox, inventor of the Maze procedure and Medical Director for ATS Medical, will lead the symposia series. The program will include a preeminent faculty of cardiac surgeons reporting on current techniques, robotics, and the future of minimally invasive cryoablation utilizing the ATS CryoMaze(TM) Surgical Ablation System.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO)
This first symposium, titled "Current Techniques, Robotics and the Future of Minimally Invasive Cryoablation" is sponsored collaboratively by ATS Medical and Intuitive Surgical, the makers of the da Vinci(R) Surgical System (Nasdaq: ISRG). The symposium follows the recent market release of Intuitive Surgical's Endowrist Cardiac Probe Grasper -- a device specifically designed to assist the da Vinci System in manipulating ATS CryoMaze Surgical Ablation Probes to complete the Cox Maze III procedure. The Symposium will be conducted on Sunday, May 11 at 7:00 pm.
"The Frontiers in Cryoablation Series will provide a forum for presenting the current capabilities of surgical cryoablation and allow physicians to collaborate on the future of minimally invasive techniques for the treatment of atrial fibrillation. I am excited about the opportunity to expand the application of cryoablation using minimal access and stand-alone procedures to maximize the benefit for surgeons and their patients," stated Dr. James Cox, Medical Director for ATS Medical.
The treatment of atrial fibrillation (AF) is believed to be the largest untapped opportunity in medical devices with an estimated multi-billion dollar market potential. In contrast, the current surgical market size is estimated at $121 million in 2007. Based on initial clinical results, management believes that only ATS has the technology -- the ATS CryoMaze Surgical Ablation System -- proven to yield clinical results similar to the conventional cut-and-sew Cox Maze III procedure, but with an approach involving small incisions. As such, the surgical AF business is expected to be a key growth opportunity for ATS in 2008 and beyond.
About ATS Medical
ATS Medical, Inc. provides innovative products and services focused on cardiac surgery. The Company, global in scope, is headquartered in Minneapolis, Minnesota. More than 145,000 ATS Open Pivot(R) Heart Valves, which utilize a unique pivot design resulting in exceptional performance and low risk profile, have been implanted in patients worldwide. The ATS 3f(R) brand encompasses multiple tissue heart valve product offerings at varying steps from market introductions to clinical trials to development projects that incorporate less invasive valve replacement technology. ATS Medical's focus on serving the cardiac surgery community is further strengthened by offerings that include ATS Simulus(R) annuloplasty products for heart valve repair and ATS CryoMaze(TM) surgical ablation products. The ATS Medical web site is http://www.atsmedical.com.
About Intuitive Surgical, Inc.
Intuitive Surgical, Inc. (Nasdaq: ISRG), headquartered in Sunnyvale, California, is the global technology leader in the field of robotic-assisted, minimally invasive surgery (MIS). Intuitive Surgical develops, manufactures and markets robotic technologies designed to improve clinical outcomes and help patients return more quickly to active and productive lives. The company's mission is to extend the benefits of minimally invasive surgery to the broadest possible base of patients. More information is available at http://www.intuitivesurgical.com and http://www.davincisurgery.com. Intuitive Surgical -- Taking surgical precision beyond the limits of the human hand. (TM)
Safe Harbor
This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management. Actual results could differ materially from those projected in the forward looking statements as a result of a number of important factors, including the results of clinical trials, the timing of regulatory approvals, the integration of 3f Therapeutics and the surgical cryoablation business of CryoCath Technologies, Inc., regulatory actions, competition, pricing pressures, supplier actions and management of growth. For a discussion of these and other risks and uncertainties that could affect the Company's activities and results, please refer to the Company's filings with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2007.
SOURCE ATS Medical, Inc.
(nasd) QMED $0.084 Annual General Meeting of Q-Med AB (publ)
Wednesday, April 30 2008 - 3:19
$-0.0058 (%-6.46)
STOCKHOLM, Sweden--(BUSINESS WIRE)--
Regulatory News:
The Annual General Meeting of Q-Med AB (publ) (STO:QMED) was held on April 29, 2008 at 3 p.m.
Dividend The meeting decided that a dividend of 1.50 SEK per share shall be paid to shareholders.
Board and fees The meeting decided to re-elect the following members of the Board: Hakan Edstrom, Bertil Hult, Anders Milton, Pia Rudengren, Asa Roden, Pernilla Strom och Bengt Agerup for the period up until the end of the next Annual General Meeting. The meeting also re-elected Pia Rudengren as the Chair of the Board.
The meeting also decided that Board fees of 1,400,000 (1,050,000) SEK in total be paid for the period 2007/2008, with 400,000 (300,000) SEK to the Chair of the Board and 200,000 (150,000) SEK to each of the other members of the Board, except for Bengt Agerup, who is an employee of the company and shall therefore not receive a Board fee.
Auditors' fees shall be paid in accordance with reasonable invoicing.
A fee of 200,000 (180,000) SEK in total shall be paid for work on the audit committee, to be divided among the three members as follows: 100,000 (90,000) SEK to the Chair of the committee and 50,000 (45,000) SEK to each of the other two committee members.
Election committee The majority of the election committee proposed that the election committee shall continue to consist of three members, with Robert Wikholm as Chair with the assignment of finding, at the latest during the third quarter, two representatives to be included in the election committee, but with the difference from previous years that one representative is to come from the major owners and one is to represent the smaller shareholders. Furthermore, it was proposed that a fee of SEK 75,000 (60,000) be paid to the election committee, to be allocated in accordance with the decision of the election committee.
The minority of the election committee, Jan-Erik Erenius, who represents AMF Pension, proposed an alternative procedure, which was supported by a number of institutional owners. The Swedish Shareholders' Association proposed a third alternative, according to which the election committee in its entirety would be elected by the Annual General Meeting. A majority of the Annual General Meeting decided in accordance with the proposal of the majority.
Principles for remuneration Finally, the meeting decided on principles for remuneration and other conditions of employment for senior management in accordance with the proposal of the Board.
Queries should be addressed to:
Q-Med AB is a rapidly growing and profitable biotechnology/medical device company. The company develops, manufactures, markets, and sells primarily medical implants. The majority of the products are based on the company's patented technology, NASHA(TM), for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: Restylane(R) for filling lines and folds, contouring and creating volume in the face, Macrolane(TM) for body contouring, Durolane(TM) for the treatment of osteoarthritis of the hip and knee joints, Deflux(R) for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, and Solesta(TM) for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q Med today has just over 700 coworkers, with close to 500 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap segment of the OMX Nordic Exchange in Stockholm.
This information was brought to you by Cision
http://newsroom.cision.com
Source: Q-Med
(nasd) MGIC $1.60 Magic Software Reports That Mr. Eitan Naor has Ceased to Serve as its President and CEO
Wednesday, April 30 2008 - 3:09
$-0.04 (%-2.44)
OR YEHUDA, Israel, April 30 /PRNewswire-FirstCall/ -- Magic Software Enterprises Ltd. (NASDAQ: MGIC), a leading provider of business integration and application development technology, today announced that Mr. Eitan Naor has ceased to serve as the Company's President and CEO. Mr. Guy Bernstein has been appointed to serve as the Company's Active Chairman.
About Magic Software Enterprises
Magic Software Enterprises Ltd. (NASDAQ: MGIC) has been a leader in enterprise application development, deployment and integration technology for more than two decades. The company's service-oriented (SOA) platforms are used by companies worldwide to develop, maintain, and deploy both legacy and new business solutions, while integrating these applications across both internal and external, heterogeneous environments. Magic Software's platform- independent methodology lets companies achieve agility by quickly assembling composite applications, allowing programmers to create services and architects and business analysts to orchestrate and reuse these services to enable business processes. Through partnerships with industry leaders such as IBM and SAP and more than 2500 ISVs worldwide, Magic Software technology is used by more than 1.5 million customers around the globe. For more information on Magic Software Enterprises Ltd. and its products and services, visit http://www.magicsoftware.com.
Magic Software is a subsidiary of the Formula Systems and Emblaze Group of companies.
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this news release include forward-looking statements that may involve a number of risks and uncertainties. Actual results may vary significantly based upon a number of factors including, but not limited to, risks in product and technology development, market acceptance of new products and continuing product conditions, both here and abroad, release and sales of new products by strategic resellers and customers, and other risk factors detailed in the Company's most recent annual report and other filings with the Securities and Exchange Commission.
Contact:
David Zigdon
+972-3-5389600
dzigdon@magicsoftware.com
SOURCE Magic Software Enterprises Ltd
(nasd) CKSW $3.07ClickSoftware Reports Record Revenues for the 1st Quarter Ended March 31, 2008
Wednesday, April 30 2008 - 3:00
$0.0704 (%2.35)
BURLINGTON, Massachusetts, April 30 /PRNewswire-FirstCall/ -- ClickSoftware Technologies Ltd. (NasdaqCM: CKSW), the leading provider of mobile workforce management and service optimization solutions, today announced results for the first quarter ended March 31, 2008.
For the first quarter ended March 31, 2008, total revenues were $11.5 million, with net income of $0.3 million, or $0.01 per share. This compares with revenues of $9.1 million and net income of $0.5 million, or $0.02 per share, for the same period last year, and revenues of $10.4 million and net income of $0.5 million, or $0.02 per share, for the fourth quarter of 2007. Excluding the effects of share-based compensation expenses related to the adoption of SFAS-123R, net income was $0.5 million, or $0.02 per share, for the first quarter of 2008.
Software license revenues for the first quarter of 2008 were $4.0 million, while service and maintenance revenues were $7.5 million. This compares to software license revenues of $3.7 million and service and maintenance revenues of $5.4 million for the same period last year, and $3.2 million and $7.2 million, respectively, in the fourth quarter of 2007.
Gross profit in the first quarter of 2008 was $6.9 million, or 60% of revenues, compared to $5.3 million, or 58% of revenues, in the same period last year, and $6.7 million, or 64% of revenues, in the fourth quarter of 2007.
Cash, cash equivalents and short and long-term investments in the first quarter of 2008 increased to $25.9 million from $24.7 million at the end of the fourth quarter of 2007. Net cash provided from operating activities was $1.4 million during the first quarter of 2008.
Management Commentary
"The first quarter was a solid start to what we believe will be a good year for ClickSoftware. We have delivered a record level of revenues, reflecting strong momentum in all geographies," said Dr. Moshe BenBassat, ClickSoftware's Chairman and Chief Executive Officer. "During the quarter, we were pleased to add Rogers Cable Communications, another industry leader, to our growing list of customers. We continued to make progress in our mid-market strategy, as demonstrated by the formation of a new partnership with Aspective, a Vodafone company, and through our achievement of Microsoft's Gold Certified Partner status. In addition, our prominent position in the just-published Gartner's 'Magic Quadrant' report for the Field Service Management industry underscores again our leadership position. Overall, we believe we are on track to continue building our Company to the next level," he added.
Outlook
The Company reiterates the previously provided year 2008 guidance of revenue growth of approximately 20%-25% over 2007, or $48-$50 million.
Investors Conference Call
ClickSoftware will host a conference call today at 9:30 a.m. EDT to discuss its financial results and other matters discussed in this press release, as well as answer questions from the investment community. To participate, please call +1-800-762-8908 and ask for the ClickSoftware conference call. International participants, please call +1-480-629-1990. The call will be available live on the internet (in listen mode only) at http://www.clicksoftware.com. A replay of this call will be available on the ClickSoftware website, or by calling 800-406-7325 (international callers can dial (+1-303-590-3030), ID Code: 3865821.
About ClickSoftware
ClickSoftware is the leading provider of mobile workforce management and service optimization solutions that create business value for service operations through higher levels of productivity, customer satisfaction and cost effectiveness. Combining educational, implementation and support services with best practices and its industry leading solutions, ClickSoftware drives service decision making across all levels of the organization. From proactive customer demand forecasting and capacity planning to real-time decision-making, incorporating scheduling, mobility and location based services, ClickSoftware helps service organizations get the most out of their resources. With over 100 customers across a variety of industries and geographies, and strong partnerships with leading platform and system integration partners - ClickSoftware is uniquely positioned to deliver superb business performance to any organization. The company is headquartered in Burlington, MA and Israel, with offices in Europe, and Asia Pacific.
For more information about ClickSoftware, please call +1-781-272-5903 or +1-888-438-3308, or visit http://www.clicksoftware.com.
This press release contains express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. These forward-looking statements include, but are not limited to, those regarding future results of operations, visibility into future periods, continued growth and rate of growth, and expectations regarding future closing of contracts and receipt of orders, recognition of revenues and deferred revenues. Such "forward-looking statements" involve known and unknown risks, uncertainties and other factors, which may cause actual results or performance to be materially different from those projected. Achievement of these results by ClickSoftware and its subsidiaries may be affected by many factors, including among others, the following: risks and uncertainties regarding the general economic outlook; the length of or change in the Company's sales cycle; the Company's ability to close sales to potential customers in a timely manner; the Company's ability to penetrate new markets; the Company's ability to maintain or increase relationships with strategic partners; timing of revenue recognition; and the Company's ability to maintain or increase its sales pipeline. The forward-looking statements contained in this press release are subject to other risks and uncertainties, including those discussed in ClickSoftware's annual report on Form 20F for the year ended December 31, 2007 and subsequent filings with the Securities and Exchange Commission. The Company is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise.
Note: Financial Schedules Attached
ClickSoftware Technologies Ltd.
CONSOLIDATED BALANCE SHEETS
(In thousands, except share data)
March 31 December 31
-------------------------
2008 2007
-------------------------
ASSETS
CURRENT ASSETS
Cash and cash equivalents $ 12,591 $ 9,054
Short-term investments 12,699 15,054
Trade receivables, net 8,571 6,883
Other receivables and prepaid
expenses 1,193 1,040
-------------------------
Total current assets 35,054 32,031
-------------------------
FIXED ASSETS
Cost 2,996 2,885
Less - accumulated depreciation 1,507 1,448
-------------------------
Total fixed assets 1,489 1,437
-------------------------
Long-term investments 640 602
Severance pay deposits 1,229 1,163
-------------------------
Total Assets $ 38,412 $ 35,233
-------------------------
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES
Accounts payable and accrued
expenses $ 7,324 $ 7,281
Deferred revenues 7,933 5,803
-------------------------
Total current liabilities 15,257 13,084
-------------------------
LONG TERM LIABILITIES
Accrued severance pay 2,569 2,418
Deferred revenues - Long term 3,264 2,919
-------------------------
Total long-term liabilities 5,833 5,337
-------------------------
Total liabilities 21,090 18,421
-------------------------
SHAREHOLDERS� EQUITY
Ordinary shares of NIS 0.02 par
value 115 115
Additional paid-in capital 73,973 73,803
Accumulated deficit (56,723) (57,063)
Treasury stock, at cost:
39,000 shares (43) (43)
-------------------------
Total shareholders' equity 17,322 16,812
-------------------------
Total liability and shareholders'
equity $ 38,412 $ 35,233
-------------------------
ClickSoftware Technologies Ltd.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share amounts)
Three Months Ended
March 31, 2008 March 31, 2007
-------------------- ------------------
% of % of
$ Revenues $ Revenues
-------------------- ------------------
Revenues:
Software license $ 3,998 35% $ 3,689 41%
Services 7,485 65% 5,369 59%
-------------------- ------------------
Total revenues 11,483 100% 9,058 100%
-------------------- ------------------
Cost of revenues:
Software license 548 5% 688 8%
Services 4,005 35% 3,074 34%
-------------------- ------------------
Total cost of revenues 4,553 40% 3,762 42%
-------------------- ------------------
Gross profit 6,930 60% 5,296 58%
-------------------- ------------------
Operating expenses:
Research and development
costs, net 1,576 14% 1,226 14%
Selling and Marketing
expenses 3,866 34% 2,961 33%
General and
administrative expenses 1,191 10% 957 10%
-------------------- ------------------
Total operating expenses 6,633 58% 5,144 57%
-------------------- ------------------
Income from operations 297 3% 152 1%
Other income - - 188 2%
Interest, net 167 1% 151 2%
-------------------- ------------------
Net income before taxes $ 464 4% $ 491 5%
-------------------- ------------------
Taxes on income 124 1% 35 0%
-------------------- ------------------
Net income $ 340 3% $ 456 5%
-------------------- ------------------
Net income per ordinary share:
Basic $ 0.01 $ 0.02
-------------------- ------------------
Diluted $ 0.01 $ 0.02
-------------------- ------------------
Shares used in computing basic
Net income per share 28,511,595 28,045,210
---------------------- ------------------
Shares used in computing
diluted Net income per share 29,654,498 29,584,633
---------------------- ------------------
Use of Non-GAAP Financial Results
In addition to disclosing financial results calculated in accordance with U.S. generally accepted accounting principles (GAAP), the Company's earnings release contains non-GAAP financial measures that exclude the effects of share-based compensation and the requirements of SFAS No. 123R, "Share-based Payment" ("123R"). The non-GAAP financial measures used by management and disclosed by the Company exclude the income statement effects of all forms of share-based compensation .The non-GAAP financial measures disclosed by the Company should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements should be carefully evaluated.
ClickSoftware Technologies Ltd.
SUPPLEMENTAL RECONCILIATIONS OF GAAP TO NON-GAAP RESULTS
(In thousands, except share and per share amounts)
Three Months Ended
March 31, 2008 March 31, 2007
-------------------- ------------------
% of % of
$ Revenues $ Revenues
-------------------- ------------------
GAAP Net income: $ 340 3% $ 456 5%
Adjustment of share-based
compensation within:
Cost of Services 24 20
Research and development
costs, net 22 16
Selling and Marketing
expenses 47 29
General and
administrative expenses 71 83
-------------------- ------------------
Net income excluding share-based
compensation $ 504 4% $ 604 7%
-------------------- ------------------
GAAP Net income per ordinary
share:
Basic $ 0.01 $ 0.02
-------------------- ------------------
Diluted $ 0.01 $ 0.02
-------------------- ------------------
Net income per ordinary share
excluding share-based
compensation:
-------------------- ------------------
Basic $ 0.02 $ 0.02
-------------------- ------------------
Diluted $ 0.02 $ 0.02
-------------------- ------------------
Contacts:
Shmuel Arvatz Adam J. Rosen
Chief Financial Officer +1-646-536-3865
+972-3-765-9467 arosen@rkequity.com
Shmuel.Arvatz@clicksoftware.com
SOURCE ClickSoftware Technologies Ltd
(nasd) OXGN $1.79OXiGENE Announces Preclinical Data Demonstrating that the Active Metabolite of ZYBRESTAT Improves Glucose Metabolism through Similar Mechanism as a Sirtuin Agonist
Wednesday, April 30 2008 - 2:00
$0.06 (%3.47)
WALTHAM, Mass.--(BUSINESS WIRE)--
OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced the publication by Zhang et al. of a paper demonstrating that combretastatin-A4, like its structural analog, resveratrol, activates cellular pathways (AMP-activated protein kinase and PPAR) involved in glucose regulation and improves glucose metabolism in a preclinical model of diabetes. Resveratrol is a stilbene compound found in red wine and other plant products that has been shown to increase healthy lifespan in animals and reduce blood glucose levels in humans with type-2 diabetes. Combrestatin-A4, a stilbene compound originally isolated from the African bush willow tree and similar in structure to resveratrol, is the active metabolite of ZYBRESTAT(TM) (fosbretabulin).
In addition, the PPAR pathway has been implicated in the pathogenesis of anaplastic thyroid cancer and other tumor types, and PPAR-agonist drugs have been shown to exert anti-tumor effects in preclinical models of anaplastic thyroid cancer and other tumor types.
"Given that the results described in Dr. Zhang's paper were obtained as part of a preclinical study, we should interpret the results cautiously; however, we believe that these results are exciting and may provide further insights into the mechanisms by which ZYBRESTAT exerts anti-tumor effects, particularly in anaplastic thyroid cancer," commented Richard Chin, M.D., President and CEO of OXiGENE. "The elucidation of this additional potential mechanism further increases our confidence that our ongoing pivotal study of ZYBRESTAT in anaplastic thyroid cancer will be successful."
The article, "Combretastatin A-4 activates AMP-activated protein kinase and improves glucose metabolism in db/db mice," by Fang Zhang and collaborators, is available online ahead of publication on the website of Pharmacological Research.
About OXiGENE
OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. The company's major focus is developing vascular disrupting agents (VDAs) that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.
About ZYBRESTAT (fosbretabulin)
ZYBRESTAT is currently being evaluated in a pivotal registration study in anaplastic thyroid cancer (ATC) under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration (FDA). OXiGENE believes that ZYBRESTAT is poised to become the first therapeutic product in a novel class of small-molecule drug candidates called vascular disrupting agents (VDAs). Through interaction with vascular endothelial cell cytoskeletal proteins, ZYBRESTAT selectively targets and collapses tumor vasculature, thereby depriving the tumor of oxygen and causing death of tumor cells. In clinical studies in solid tumors, ZYBRESTAT has demonstrated potent and selective activity against tumor vasculature, as well as clinical activity against ATC, ovarian cancer, and various other solid tumors. In clinical studies in patients with forms of macular degeneration, intravenously-administered ZYBRESTAT has demonstrated clinical activity, and the Company is working to develop a convenient and patient-friendly topical formulation of ZYBRESTAT for ophthalmological indications.
Safe Harbor Statement
This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release may turn out to be wrong. Forward-looking statements can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties, including, but not limited to, the significance of the preclinical results referred to in this press release for the Company's ongoing Phase II/III clinical trial of ZYBRESTAT in anaplastic thyroid cancer. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in OXiGENE's reports to the Securities and Exchange Commission, including OXiGENE's reports on Form 10-K, 10-Q and 8-K. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise. Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2007.
Source: OXiGENE, Inc.
Iranian president launches Sri Lanka refinery upgrade
Ranga Sirilal
Reuters North American News Service
Apr 29, 2008 05:31 EST
COLOMBO, April 29 (Reuters) - Iranian President Mahmoud Ahmadinejad launched a project to boost the capacity of Sri Lanka's main oil refinery on Tuesday, part of a $1.5 billion loan to the government as Iran extends its energy ties in South Asia.
Ahmadinejad's visit came as President Mahinda Rajapaksa, increasingly isolated over criticism from Western countries about its human rights record in a 25-year-old civil war with Tamil Tiger separatists, seeks closer ties with Asian countries.
Ahmadinejad, who visited Pakistan in Monday to seal a $7.6 billion pipeline deal opposed by the United States, will travel later on Tuesday to India, which is also interested in the pipeline to feed its booming economy.
"We can ensure security and fair play for all ... but in the world some powerful nations do not allow such a situation and they have created divisions among people and nationalities," Ahmadinejad said at the launch in remarks through an interpreter.
"The peoples of Sri Lanka and Iran are against the policies of the nations who are the enemies of the humanity."
Iran had pledged a $1.5 billion loan to fund a raft of infrastructure projects in Sri Lanka, including boosting oil refinery capacity and a 100-megawatt hydropower project.
The project aims to boost production of Sri Lanka's existing Sapugaskanda oil refinery in Colombo from 50,000 barrels per day to 100,000 bpd.
Hours before Ahmadinejad arrived in Colombo, the national power grid crashed for the second time in a month, underlining the precarious state of Sri Lanka's infrastructure.
Building new or upgrading existing infrastructure has been a low priority in the island nation because of the civil war between the state and Tamil Tiger rebels that has killed more than 70,000 people.
In Islamabad on Monday, Iran and Pakistan said they had settled all issues relating to plans for the gas pipeline.
Linking the world's second-largest gas reserves to the fast-growing South Asian economies, it could be completed by 2012.
The pipeline will be top of the agenda when Ahmadinejad travels to India.
It would initially transport 60 million cubic metres of gas (2.2 billion cubic feet) daily to Pakistan and India, half for each country, but capacity would be raised later to 150 million cubic metres. (Editing by Alistair Scrutton and David Fogarty)
Source: Reuters North American News Service
Russia to examine Iran's nuclear ideas - report
Zahra Hosseinian
Reuters North American News Service
Apr 29, 2008 10:11 EST
TEHRAN, April 29 (Reuters) - Russia was quoted as saying on Tuesday it was ready to examine Iranian proposals to end a deadlock over Tehran's disputed nuclear programme.
Iranian media said Valentin Sobolev, acting secretary of Russia's National Security Council, made the comments at talks with top Iranian nuclear negotiator Saeed Jalili.
On Monday Jalili said Iran had drawn up "serious" ideas to end the atomic row.
The United States and European states accuse the Islamic Republic of mastering technology to make nuclear weapons under cover of a civilian programme. Iran says its goal is peaceful.
Iran's official IRNA news agency, citing Sobolev, said that "Russia was ready to examine Iran's proposed package and to find a way out of this existing deadlock."
"Russia supports the Islamic Republic of Iran's right in using peaceful nuclear energy," it quoted Sobolev as saying. He is expected to meet President Mahmoud Ahmadinejad and Foreign Minister Manouchehr Mottaki before leaving Iran on Wednesday.
Iran has not revealed details about its proposals.
"Iran's proposed package is a new chance for constructive cooperation aimed at creating regional and international peace and stability," Jalili said.
Iran's failure to convince world powers about its intentions has led to three rounds of U.N. sanctions since 2006. Russia and China have been reluctant backers of imposing penalties.
The U.N. Security Council has demanded Iran halt uranium enrichment, the part of Tehran's nuclear programme that most worries the West because it can be used to make fuel for power plants or, if desired, material for bombs. Iran has refused.
Russia, which this year finished shipping nuclear fuel to Iran's first nuclear power station, has tried to use a mixture of persuasion and warnings to push Iran to be more open about its nuclear programme.
A senior diplomat in Europe said Iran had earlier proposed turning its Natanz enrichment complex into a multilateral operation to counter foreign fears of diversions to bomb making there, and that this might be among Iran's proposals.
Iran's Mehr News Agency said Swiss Foreign Minister Micheline Calmy-Rey, whose country has previously sought to find a compromise in the atomic row, spoke to Jalili by telephone about the proposals and "welcomed Iran's initiative".
There was no immediate comment from Swiss officials. (Writing by Edmund Blair, edited by Richard Meares)
Source: Reuters North American News Service
EU set to blacklist top Iranian bank
--------------------------------------------------------------------------------
Herb Keinon , THE JERUSALEM POST Apr. 28, 2008
--------------------------------------------------------------------------------
Following a long-delayed green light from Italy, the EU is poised in the coming days to slap sanctions on one of Iran's most influential banks, in a move praised in Jerusalem as "very important."
The Jerusalem Post has learned that at last Friday's meeting of the EU's Political and Security Committee (PSC) in Brussels, Italy removed its objection to placing Bank Melli, Iran's largest bank, on a list of Iranian institutions and personalities that the EU would boycott. Government sources said this was an early indication that new Italian Prime Minister Silvio Berlusconi seemed intent on steering a different Italian policy toward Iran.
Up until Friday, Italy - Iran's largest trading partner in Europe - was the most vocal opponent to placing this bank on the list. Italy was joined in this opposition by Austria, Spain and Cyprus. Those countries, following Italy's lead, have now removed their objections as well.
The addition of Bank Melli to the list is considered significant because this bank is one of the major vehicles through which business between Iran and the EU is channeled.
The latest round of UN Sanctions against Iran - Security Council Resolution 1803, adopted in March - called for all states to "exercise vigilance over the activities of financial institutions in their territories with all banks domiciled in Iran, in particular with Bank Melli and Bank Saderat."
The EU, by now putting the bank on its black list, has ratcheted up those sanctions a notch, joining the US, which took unilateral sanctions against the bank last October.
A US Department of Treasury statement at the time explained its sanctions against the bank by saying that Melli "provides banking services to entities involved in Iran's nuclear and ballistic missile programs," and that it also provided banking services to the Islamic Revolutionary Guards and its Quds force, which "provides material support to the Taliban, Lebanese Hizbullah, Hamas, Palestinian Islamic Jihad, and the Popular Front for the Liberation of Palestine-General Command (PFLP-GC)."
One government source said the EU move would be a real blow to the Iranians, both because Melli was an important bank and because the decision sent a strong political message to Teheran that its support inside the EU was not as strong as it had once thought.
"This is definitely significant, because Iran sees the EU as a major economic partner," the source said. The source said that as Teheran was having increasing difficulties doing business with Europe, it was looking east to countries like China, Indonesia and Malaysia to provide it with spare parts and technological upgrades.
What those countries couldn't provide, however, and what Iran needed desperately for its energy industry, was Western technology, the source said.
The decision to blacklist Bank Melli was made at last Friday's PSC meeting, where a discussion was held on the formulation of an EU "common position" on the UN sanctions taken against Iran in March. Following the first two rounds of sanctions in 2007, the EU went a little further than the UN Security Council and in its "common position" drew up a list of personalities and institutions it would boycott.
The PSC is a group of ambassadors from each of the EU states, making up the highest political-level echelon stationed permanently in Brussels. It prepares the resolutions that are later approved by the EU ministers.
What was agreed upon at the PSC, government sources said, was to take the current EU list of blacklisted Iranian people and institutions and expand it to include Bank Melli. It is expected to be approved by EU ministers in a number of days, possibly by the EU foreign ministers when they meet for their monthly meeting on Friday.
However, no decision has yet been made on a "common position" on Resolution 1803, with Italy still among those opposing a British and French resolution to intensify those sanctions as well.
Even as the EU's move was seen as a positive development in Jerusalem, there was continued concern here that the $28 billion deal signed last month between the Swiss energy giant EGL and the state-owned National Iranian Gas Export Co. might open up the dam and lead others to invest there as well.
Officials in Jerusalem explained that the main concern was not business trade with Iran, but rather investment in Iran's energy sector. The official said there were some signs that following the Swiss example - which received Swiss political backing when the country's Foreign Minister Micheline Calmy-Rey went to Teheran to witness the signing of the deal - some countries with smaller economies, such as Croatia and Poland, might follow suit with smaller deals.
Although the Swiss deal did not violate the letter of the UN sanctions, sources in Jerusalem said, it did violate the spirit of the sanctions, which was to send a clear message that Iran was not a safe place for investments.
Switzerland is not an EU member.
"Hostile" Iran Sparks U.S. Attack Plan
April 29, 2008
--------------------------------------------------------------------------------
(CBS) A second American aircraft carrier steamed into the Persian Gulf Tuesday as the Pentagon ordered military commanders to develop new options for attacking Iran. CBS News national security correspondent David Martin reports that the planning is being driven by what one officer called the "increasingly hostile role" Iran is playing in Iraq - smuggling weapons into Iraq for use against American troops.
"What the Iranians are doing is killing American servicemen and -women inside Iraq," said Secretary of Defense Robert Gates.
U.S. officials are also concerned by Iranian harassment of U.S. ships in the Persian Gulf as well as Iran's still growing nuclear program. New pictures of Iran's uranium enrichment plant show the country's defense minister in the background, as if deliberately mocking a recent finding by U.S. intelligence that Iran had ceased work on a nuclear weapon.
No attacks are imminent and the last thing the Pentagon wants is another war, but Chairman of the Joint Chiefs of Staff Mike Mullen has warned Iran not to assume the U.S. military can't strike.
"I have reserve capability, in particular our Navy and our Air Force so it would be a mistake to think that we are out of combat capability," Mullen said.
Targets would include everything from the plants where weapons are made to the headquarters of the organization known as the Quds Force which directs operations in Iraq. Later this week Iraqi Prime Minister Nouri al-Maliki is expected to confront the Iranians with evidence of their meddling and demand a halt.
If that doesn't produce results, the State Department has begun drafting an ultimatum that would tell the Iranians to knock it off - or else.
© MMVIII, CBS Interactive Inc. All Rights Reserved.
Israeli general warns militants aim for holiday attack By MARK LAVIE, Associated Press Writer
Tue Apr 29, 2:28 PM ET
The commander of Israeli military intelligence warned Tuesday that Palestinian militants will try to stage a large-scale attack on Israel's 60th anniversary celebrations next month.
"There are attempts to carry out a 'quality' attack of either kidnapping Israeli civilians or a major bombing" during the celebrations, Maj. Gen. Amos Yadlin was quoted as saying in a text released by the prime minister's office.
Speaking at closed Cabinet session, Yadlin compared the potential attack to the suicide bombing on a Jewish holiday in 2002 that killed 30 people in a hotel on Israel's coast.
Israel is expected to impose strict security measures, including a ban on Palestinians entering the country, around the time of Israel's Independence Day on May 8. President Bush is among the VIPs expected to attend the festivities.
Palestinians mark the occasion as a day of mourning, because about 700,000 Palestinians fled their homes or were driven out during the two-year war that followed Israel's creation in 1948.
Yadlin spoke as Israel and the Palestinians traded charges over who was to blame for the death of a mother and her four children in an explosion Monday at their house during a clash in the Gaza Strip.
Before the Cabinet's closed meeting, Israeli Prime Minister Ehud Olmert made a public statement expressing regret over the deaths.
But he blamed Gaza's Hamas rulers, saying they allow militants to operate within residential areas and make "the civilian population in Gaza into an indivisible part of its war."
The fighting erupted after Israeli soldiers entered the town of Beit Hanoun in pursuit of gunmen who approached a border patrol, Israel said.
Palestinian officials and relatives on Monday blamed the blast on an Israeli tank shell. But the Palestinian Center for Human Rights said Tuesday it was caused by an air-fired Israeli missile aimed at a militant about 30 feet from the home. The group gathers its information from witness accounts.
The Israeli human rights group B'Tselem demanded the military release video from the aircraft that fired missiles in Beit Hanoun, so ballistics experts could determine whether there was a secondary blast caused by militants' explosives, as Israeli officials claim.
A military commission headed by a colonel is expected to report Wednesday on its investigation of the incident.
Egypt has been trying for weeks to arrange a cease-fire between Israel and Gaza militant groups.
Last week, Hamas said it would accept a six-month cease-fire with Israel, provided Israel ends the economic blockade it imposed on Gaza after Hamas violently wrested control of the coastal territory last June. The blockade has caused shortages of fuel, cement and other basic items and has deepened unemployment in the impoverished territory.
As several human rights groups called Tuesday for Israel to relax its restrictions on fuel shipments to Gaza, Yadlin blamed Hamas for the fuel shortage, telling the Israeli Cabinet that the Islamic militant group "is exploiting the situation to give the illusion of a crisis."
Israeli Defense Minister Ehud Barak scoffed at talk of truce efforts.
"I think now we're in a showdown with Hamas," Barak told reporters. "That's a more apt description than a possible cease-fire."
While clashing with militants in Gaza, Israel is engaged in peace talks with Hamas' chief rival, Palestinian President Mahmoud Abbas, who government is based in the West Bank.
In August, Israel offered to stop hunting dozens of West Bank militants linked to Abbas if they agreed to halt violent activities. Six months later, a senior Israeli security official said the amnesty program has been a success.
Militants seeking amnesty are required to surrender their weapons, serve a brief sentence in a Palestinian jail and pass a probationary term.
According to the official, 281 gunmen have accepted the offer, and just six have returned to violence. The official's identity could not be revealed under Israel's security guidelines.
US military deaths in Iraq at 4,058 By The Associated Press
14 minutes ago
As of Tuesday, April 29, 2008, at least 4,058 members of the U.S. military have died since the beginning of the Iraq war in March 2003, according to an Associated Press count. The figure includes eight military civilians. At least 3,306 died as a result of hostile action, according to the military's numbers.
The AP count is one more than the Defense Department's tally, last updated Tuesday at 10 a.m. EDT.
The British military has reported 176 deaths; Italy, 33; Ukraine, 18; Poland, 21; Bulgaria, 13; Spain, 11; Denmark, seven; El Salvador, five; Slovakia, four; Latvia, three; Estonia, Netherlands, Thailand, Romania, two each; and Australia, Hungary, Kazakhstan, South Korea, one death each.
Since the start of U.S. military operations in Iraq, 29,911 U.S. service members have been wounded in hostile action, according to the Defense Department's weekly tally.
___
The latest deaths reported by the military:
• A soldier was killed Tuesday by small-arms fire in northwestern Baghdad.
• A soldier was killed Tuesday when an explosive struck his vehicle in northwestern Baghdad.
___
The latest identifications reported by the military:
• No identifications reported.
___
On the Net:
http://www.defenselink.mil/news/
Scheduled Earnings Releases for Wednesday, April 30, 2008
Before Market Opens
Ticker Company Period Estimate
EGHT 8x8 Inc Q4 2008 $0.00
T.ADV ADDENDA CAP INC N/A
ASX Advanced Semiconductor Engineering Inc. Q1 2008 $0.08
ADVNA ADVANTA Corp. N/A
ALU AlcatelLucent Q1 2008 ($0.02)
ALXN Alexion Pharmaceuticals Inc. Q1 2008 ($0.44)
AMED Amedisys Inc Q1 2008 $0.57
APU AmeriGas Propane, Inc Q2 2008 $1.73
ARGN Amerigon Inc. Q1 2008 $0.07
AACC Asset Acceptance Capital Corp. Q1 2008 $0.20
ATBC ATLANTIC BANCGROUP N/A
AUXL Auxilium Pharmaceuticals Inc. Q1 2008 ($0.32)
AVGN Avigen Inc. Q1 2008 ($0.25)
AVA Avista Corp. Q1 2008 $0.50
BEC Beckman Coulter Inc. Q1 2008 $0.68
BLT Blount International Inc. Q1 2008 $0.14
BNCC Bnccorp Inc. N/A
BAM Brookfield Asset Management Inc. Ltd. Q1 2008 $0.25
BOBJ Business Objects S.A. N/A
CACH Cache Inc. Q1 2008 ($0.02)
CADA CAM Commerce Solutions Inc. Q2 2008 $0.30
CPLP Capital Product Partners L.P. Common Units Q1 2008 $0.37
CDI CDI Corp. Q1 2008 $0.40
T.COS CDN OIL SANDS Q1 2008 $0.74
CNP CenterPoint Energy Inc. Q1 2008 $0.39
CETV Central European Media Enterprises Ltd. Q1 2008 $0.34
CPF Central Pacific Financial Corp. Q1 2008 $0.39
CBI Chicago Bridge & Iron Company N.V. Q1 2008 $0.55
CBB Cincinnati Bell Inc. Q1 2008 $0.09
CINF Cincinnati Financial Corp. Q1 2008 $0.74
CLRO ClearOne Communications Inc. N/A
CKSW ClickSoftware Technologies Ltd. Q1 2008 $0.02
CL ColgatePalmolive Company Q1 2008 $0.88
CSHB Community Shores Bank Corp. Q1 2008 N/A
CGX Consolidated Graphics Inc. Q4 2008 $1.16
CEG Constellation Energy Group Inc. Q1 2008 $1.35
COCO Corinthian Colleges Inc. Q3 2008 $0.15
CRY CryoLife Inc. Q1 2008 $0.09
CMI Cummins Inc. Q1 2008 $0.91
CRIS Curis Inc. N/A
DF Dean Foods Company Q1 2008 $0.20
DBD Diebold Inc. 2007 $0.23
ELON Echelon Corp. Q1 2008 ($0.17)
EDGW Edgewater Technology Inc. Q1 2008 $0.10
EFJI EFJ Inc. Q1 2008 ($0.16)
ELMG EMS Technologies Inc. Q1 2008 $0.25
ENDP Endo Pharmaceuticals Holdings Inc. Q1 2008 $0.47
ENTG Entegris Inc. Q1 2008 $0.06
EEFT Euronet Worldwide Inc. Q1 2008 $0.27
FSLR First Solar Inc. 2008 $0.47
FED Firstfed Financial Corp. Q1 2008 $0.33
FORR Forrester Research Inc. Q1 2008 $0.23
FPL FPL Group Inc. Q1 2008 $0.81
FMS Fresenius Medical Care AG & Co. KGaA Q1 2008 $0.63
FTD FTD Group Inc. Q3 2008 $0.39
GRMN Garmin Ltd. Q1 2008 $0.75
GLS Genesis Lease Ltd. Q1 2008 $0.32
GOL GOL Linhas Areas Inteligentes S.A. 2007 $0.10
GLF GulfMark Offshore Inc. Q1 2008 $1.11
HW Headwaters Inc. Q2 2008 $0.02
HNT Health Net Inc. Q1 2008 $0.66
HES Hess Corp. Q1 2008 $1.92
IACI IAC/InterActiveCorp Q1 2008 $0.25
ILOG ILOG S.A. N/A
INCY Incyte Corp. Q1 2008 ($0.47)
IDEV Indevus Pharmaceuticals Inc. Q2 2008 ($0.23)
IR Ingersoll-Rand Company Limited Q1 2008 $0.72
NSUR Insure.com Inc. N/A
IP International Paper Company Q1 2008 $0.52
IONA IONA Technologies PLC Q1 2008 ($0.02)
JNY Jones Apparel Group Inc. Q1 2008 $0.37
K Kellogg Company Q1 2008 $0.76
KFT Kraft Foods Inc. Q1 2008 $0.41
LM Legg Mason Inc. Q4 2008 $0.06
LFUS Littelfuse Inc. Q1 2008 $0.36
LOJN LoJack Corp. Q1 2008 $0.04
MHO M/I Homes Inc. Q1 2008 ($1.46)
MKTAY Makita Corp. N/A
MWV MeadWestvaco Corp. Q1 2008 ($0.01)
MNST Monster Worldwide Inc. WhisperingsTM Q1 2008 $0.22
MPS MPS Group Inc. Q1 2008 $0.20
NOV National Oilwell Varco Inc. WhisperingsTM Q1 2008 $1.09
NJR New Jersey Resources Corp. Q2 2008 $1.89
OMX OfficeMax Inc. Q1 2008 $0.69
ZEUS Olympic Steel Inc. Q1 2008 $0.97
OPY Oppenheimer Holdings Inc. N/A
ORCT Orckit Communications Ltd. Q1 2008 ($0.55)
PTI Patni Computer Systems Ltd. Q1 2008 $0.26
PG Procter & Gamble Company Q3 2008 $0.81
QSC Questcor Pharmaceuticals Inc N/A
FRZ Reddy Ice Holdings Inc. Q1 2008 ($0.42)
RHB RehabCare Group Inc. Q1 2008 $0.25
RELV Reliv International Inc. Q1 2008 $0.08
IRN Rewards Network Inc Q1 2008 $0.00
RAI Reynolds American Inc. Q1 2008 $1.15
ROC Rockwood Holdings Inc. Q1 2008 $0.50
RSTI RofinSinar Technologies Inc. Q2 2008 $0.52
SNY SanofiAventis Q1 2008 $2.48
SAP SAP Aktiengesellschaft Q1 2008 $0.43
SEE Sealed Air Corp. Q1 2008 $0.39
SI Siemens Aktiengesellschaft Q2 2008 $1.50
SLAB Silicon Laboratories Inc. WhisperingsTM Q1 2008 $0.22
SPIL Siliconware Precision Industries Company Ltd. Q1 2008 $0.14
SSBX Silver State Bancorp Q1 2008 $0.27
SO Southern Company Q1 2008 $0.42
SPW SPX Corp. Q1 2008 $0.98
STEL Stellent, Inc Q1 2008 $0.32
STC Stewart Information Services Corp. Q1 2008 ($0.81)
STRA Strayer Education Inc. Q1 2008 $1.58
TLM Talisman Energy Inc. 2007 $0.49
TSTY Tasty Baking Company Q1 2008 $0.00
TAYC Taylor Capital Group Inc. Q1 2008 $0.17
BCO The Brinks Company Q1 2008 $0.79
IPG The Interpublic Group of Companies Inc. Q1 2008 ($0.16)
TWC Time Warner Cable Inc. Q1 2008 $0.22
TWX Time Warner Inc. Q1 2008 $0.23
TKR Timken Company Q1 2008 $0.72
TRX Tronox Inc. Q1 2008 ($0.35)
TRW TRW Automotive Holdings Corp. Q1 2008 $0.62
T.X TSX GRP INC-TS Q1 2008 $0.62
UGI UGI Corporation Q2 2008 $1.18
UIS Unisys Corp. Q1 2008 $0.01
UMC United Microelectronics Corp. Q1 2008 $0.01
VPHM ViroPharma Inc. Q1 2008 $0.23
VC Visteon Corp. Q1 2008 ($0.65)
WBC WABCO Holdings Inc. Q1 2008 $0.91
WBK Westpac Banking Corp. Q2 2008 N/A
WXS Wright Express Corp. WhisperingsTM Q1 2008 $0.44
During Market Hours
Ticker Company Period Estimate
SERC SVC BANCORP INC N/A
After Market Closes
Ticker Company Period Estimate
ACE ACE Ltd. Q1 2008 $1.93
AKAM Akamai Technologies Inc. WhisperingsTM Q1 2008 $0.29
ALEX Alexander & Baldwin Inc. Q1 2008 $0.88
AYE Allegheny Energy Inc. Q1 2008 $0.78
AIQ Alliance Imaging Inc. Q1 2008 $0.07
AW Allied Waste Industries Inc. Q1 2008 $0.17
MDRX Allscripts Healthcare Solutions Inc Q1 2008 $0.10
ASGR America Service Group Inc. Q1 2008 $0.06
ANE American Community Newspapers Inc N/A
AMKR Amkor Technology Inc. Q1 2008 $0.26
ANDS Anadys Pharmaceuticals Inc. Q1 2008 ($0.25)
ANIK Anika Therapeutics Inc. Q1 2008 $0.08
AHT Ashford Hospitality Trust Inc. Q1 2008 $0.31
AHL Aspen Insurance Holdings Ltd. Q1 2008 $1.12
ATN Atlas Energy Resources LLC Q1 2008 $0.60
ATML Atmel Corp. WhisperingsTM Q1 2008 $0.01
AVB AvalonBay Communities Inc. Q1 2008 $1.22
AXTI AXT Inc Q1 2008 $0.04
BGF B&G Foods Inc. Enhanced Income Securities N/A
BANR Banner Corp. Q1 2008 $0.35
BFSB BEDFORD BANCSHARES INC N/A
BGFV Big 5 Sporting Goods Corp. Q1 2008 $0.19
BMR BioMed Realty Trust Inc. Q1 2008 $0.46
BLOG BladeLogic Inc. N/A
BDN Brandywine Realty Trust Q1 2008 $0.62
CBT Cabot Corp. Q2 2008 $0.40
COG Cabot Oil & Gas Corp. Q1 2008 $0.50
CAI CACI International Inc Q3 2008 $0.69
CAP CAI International Inc. Q1 2008 $0.30
DVR Cal Dive International Inc. Q1 2008 $0.16
CWT California Water Service Group Q1 2008 $0.09
CALD Callidus Software Inc. Q1 2008 ($0.06)
CLLDY Capitaland Ltd N/A
CSCX Cardiac Science Corp. Q1 2008 $0.08
CBL CBL & Associates Properties Inc. Q1 2008 $0.79
CDR Cedar Shopping Centers Inc. Q1 2008 $0.31
CTX Centex Corp. Q4 2008 ($2.56)
CEDC Central European Distribution Corp. Q1 2008 $0.28
CIR CIRCOR International Inc. Q1 2008 $0.76
CLRT Clarient Inc. Q1 2008 ($0.04)
CNQR Concur Technologies Inc. Q2 2008 $0.08
XRAY DENTSPLY International Inc. Q1 2008 $0.43
DNEX Dionex Corp. Q3 2008 $0.68
DRC DresserRand Group Inc. Q1 2008 $0.24
DTE DTE Energy Company Q1 2008 $0.74
DRE Duke Realty Corp. Q1 2008 $0.63
DRCO Dynamics Research Corp. Q1 2008 $0.15
EQR Equity Residential Q1 2008 $0.59
ERIE Erie Indemnity Company Q1 2008 $0.80
ESS Essex Property Trust Inc. Q1 2008 $1.63
FARO FARO Technologies Inc. Q1 2008 $0.26
FGXI FGX International Q1 2008 $0.08
FFBC First Financial Bancorp. Q1 2008 $0.20
FMR First Mercury Financial Corp. Q1 2008 $0.56
FISV Fiserv Inc. WhisperingsTM Q1 2008 $0.76
FLDR Flanders Corp. Q1 2008 $0.06
FPIC FPIC Insurance Group Inc. Q1 2008 $1.16
GNK Genco Shipping & Trading Ltd. Q1 2008 $1.46
GMR General Maritime Corp. Q1 2008 $0.63
GCFB Granite City Food & Brewery Ltd Q1 2008 ($0.20)
GVA Granite Construction Inc. Q1 2008 $0.05
GW Grey Wolf Inc Q1 2008 $0.14
GSIG GSI Group Inc. Q1 2008 $0.06
HWFG Harrington West Financial Group Inc. Q1 2008 $0.35
HVT Haverty Furniture Companies Inc. Q1 2008 ($0.03)
HA Hawaiian Holdings Inc Q1 2008 ($0.40)
HLX Helix Energy Solutions Group Inc. Q1 2008 $0.82
HTBK Heritage Commerce Corp Q1 2008 $0.27
HTCO Hickory Tech Corp. N/A
HMN Horace Mann Educators Corp. Q1 2008 $0.43
INSP InfoSpace Inc. Q1 2008 $0.03
IOSP Innospec Inc. Q1 2008 $0.37
IRBT iRobot Corp. Q1 2008 ($0.15)
ISTA ISTA Pharmaceuticals Inc. Q1 2008 ($0.38)
ITC ITC Holdings Corp. Q1 2008 $0.50
ITRI Itron Inc. Q1 2008 $0.69
JDSU JDS Uniphase Corp. WhisperingsTM Q3 2008 $0.09
KONA Kona Grill Inc. Q1 2008 ($0.07)
LMAT LeMaitre Vascular Inc. Q1 2008 ($0.07)
LHCG LHC Group Q1 2008 $0.28
LOOP LoopNet Inc. Q1 2008 $0.12
MANT ManTech International Corp. Q1 2008 $0.56
MTXX Matrixx Initiatives Inc. Q4 2008 $0.44
MCRS MICROS Systems Inc. Q3 2008 $0.29
MIPS MIPS Technologies Inc. Q3 2008 $0.02
MRT Mortons Restaurant Group Inc. Q1 2008 $0.13
MRVC MRV Communications Inc. Q1 2008 ($0.01)
MUR Murphy Oil Corp. Q1 2008 $1.86
NC NACCO Industries Inc. N/A
NVT NAVTEQ Corp. Q1 2008 $0.33
NWK Network Equipment Technologies Inc. Q4 2008 $0.07
NBIX Neurocrine Biosciences Inc. Q1 2008 ($0.54)
NEWP Newport Corp. Q1 2008 $0.09
NTLS NTELOS Holdings Corp. Q1 2008 $0.18
OIIM O2Micro International Ltd. WhisperingsTM Q1 2008 $0.03
OII Oceaneering International Inc. Q1 2008 $0.73
OMTR Omniture Inc. WhisperingsTM Q1 2008 ($0.01)
OKE ONEOK Inc. Q1 2008 $1.46
OKS Oneok Partners L.P. Q1 2008 $1.10
OI OwensIllinois Inc. Q1 2008 $0.79
PMII PARA MAS INTERNET INC Q1 2008 ($0.70)
PEAK Peak International Ltd. N/A
PSEM Pericom Semiconductor Corp. Q3 2008 $0.15
PGTI PGT Inc. Q1 2008 ($0.03)
PAA Plains All American Pipeline L.P. Q1 2008 $0.63
PPO Polypore International Inc. Q1 2008 $0.22
PRU Prudential Financial Inc. Q1 2008 $1.82
PSYS Psychiatric Solutions Inc. Q1 2008 $0.42
LQ QUINENCO S A N/A
RADS Radiant Systems Inc. Q1 2008 $0.09
O Realty Income Corp. Q1 2008 $0.48
RNOW RightNow Technologies Inc. Q1 2008 ($0.15)
ROG Rogers Corporation Q1 2008 $0.41
SGMO Sangamo BioSciences Inc. Q1 2008 ($0.16)
SBAC SBA Communications Corp. WhisperingsTM Q1 2008 ($0.09)
SCRX Sciele Pharma Inc. Q1 2008 $0.35
SQNM Sequenom Inc. Q1 2008 ($0.16)
SFLY Shutterfly Inc. Q1 2008 ($0.15)
SJW SJW Corp. Q1 2008 $0.12
SFBC Slades Ferry Bancorp N/A
SSS Sovran Self Storage Inc. Q1 2008 $0.82
SBUX Starbucks Corp. Q2 2008 $0.18
STNR Steiner Leisure Ltd. Q1 2008 $0.56
SUN Sunoco Inc. WhisperingsTM Q1 2008 ($0.09)
SMCI Super Micro Computer Inc. Q3 2008 $0.14
SYMC Symantec Corp. Q4 2008 $0.29
SMMX Symyx Technologies Inc. Q1 2008 ($0.18)
SKT Tanger Factory Outlet Centers Q1 2008 $0.61
TTEK Tetra Tech Inc. Q2 2008 $0.20
TLGD Tollgrade Communications Inc. Q1 2008 ($0.05)
TCBK TriCo Bancshares Q1 2008 $0.34
TRN Trinity Industries Inc. Q1 2008 $0.72
TTMI TTM Technologies Inc. Q1 2008 $0.21
ULTI Ultimate Software Group Inc. Q1 2008 $0.04
UDRL Union Drilling Inc. Q1 2008 $0.20
UNM Unum Group Q1 2008 $0.57
UQM UQM Technologies Inc N/A
VVC Vectren Corp. Q1 2008 $0.91
VNBC Vineyard National Bancorp Q1 2008 $0.07
VIRL Virage Logic Corp. Q2 2008 $0.00
VLCM Volcom Inc. Q1 2008 $0.21
WCAA WCA Waste Corp. Q1 2008 $0.03
WGL WGL Holdings Inc. Q2 2008 $1.40
WSH Willis Group Holdings Ltd. Q1 2008 $1.17
TRCR 6.5% hod fwiw
TRCR going for hod fwiw
tomorrow, who's holding till then lol
TMY .74 +60% fwiw round II
Looks that way, at this point I'd like to gice up on it and cash out myself lol. Where's the bounce?
tmy .71 x .72